Skip to Content

'
Guillermo Garcia-Manero, M.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Chief, Section of Myelodysplastic Syndromes, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Deputy Chair, Translational Research, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Co-Chair, MDS Clinical Research Consortium, Rockville, MD

Education & Training

Degree-Granting Education

1991 University of Zaragoza, Spain, MD, Medical Doctor
1985 Colegio "Luis Vives", Palma de Mallorca, Spain, Bachillerato, Pre-Med

Postgraduate Training

1996-1999 Clinical Fellowship, Hematology and Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA
1993-1996 Clinical Internship and Residency, Thomas Jefferson University Hospital, Philadelphia, PA

Board Certifications

1999 Medical Oncology
1999 Hematology Eligible
1996 Internal Medicine

Experience/Service

Academic Appointments

Regular Member, Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston Graduate School of Biomedical Sciences, Houston, TX, 6/2004-8/2017

Other Appointments/Responsibilities

Global MDS/AML Steering Committee, Celgene, Orlando, FL, 12/2010-present
Medical Advisory Board, Aplastic Anemia & MDS International Foundation, Rockville, MD, 2010-2012

Institutional Committee Activities

Steering Committee Member, MD Anderson Cancer Moon Shots, 3/2012-present
Leader, AML / MDS Moon Shot, 2012-present
Member, Clinical Research Impact Committee, 2008-present
Reviewer, Institutional Research Grant Committee, 2007-present
Member, Division of Cancer Medicine Fellowship Committee, 2/2005-present
Member, DoCM Research Sub-Committee, 9/2003-present
Member, Transfusion Committee, 5/2002-present
Member, MD Anderson International Spain Committee, 4/2001-present

Honors and Awards

2009 Celgene Young Investigator Award for Clinical Research in Hematology, American Society of Hematology
2009 Emil J. Frei, III Award for Excellence in Translational Research, The University of Texas MD Anderson Cancer Center
2008 Faculty Scholar Award, The University of Texas MD Anderson Cancer Center
2007 Faculty Educator of the Month, The University of Texas MD Anderson Cancer Center
2002 Physician-Scientist Program, The University of Texas MD Anderson Cancer Center
2001 Career Development Award, American Society of Clinical Oncology
1998 Winner, Oncology Research Competition, Delaware Valley Hematology Oncology Association
1994 Research Award for Clinical Trainees Program, National Institutes of Health
1991 Fellowship, European Society of Human Genetics
1990 Research Student Award, University of Zaragoza

Professional Memberships

American Association for the Advancement of Science
Member, 1993-present
American Association of Cancer Research
Chair, Scientific Review Committee, 1/2009-present
Member, 2001-present
American Medical Association (AMA) Foundation, Chicago, IL
Selection Committee, 1/2010-present
American Society of Clinical Oncology
Member, 1998-present
American Society of Hematology, Washington, DC
Abstract Reviewer for Annual Meeting, 2011
Member, 1997-present
Aplastic Anemia & MDS International Foundation, Rockville, MD
Medical Advisory Board, 2011-present
Jefferson Medical College Alumni Association
Member, 2000-present
London Goodenough Trust, London, United Kingdom
Life Member, 1990-present
Peruvian Society of Oncology
Honorary Member, 10/2003-present
Southwest Oncology Group (SWOG)
Member, Steering Committee, 2013-present
Southwest Oncology Group (SWOG)
Group Member, 2012
The Aplastic Anemia and International Myelodysplastic Syndromes Foundation, NJ
Member, Steering Committee, 2007-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Attieh Y, Geng QR, Dinardo CD, Zheng H, Jia Y, Fang ZH, Gañán-Gómez I, Yang H, Wei Y, Kantarjian H, Garcia-Manero G. Low frequency of H3.3 mutations and upregulated DAXX expression in MDS. Blood 121(19):4009-11, 5/9/2013. PMID: 23660862.
2. Al-Kali A, Quintás-Cardama A, Luthra R, Bueso-Ramos C, Pierce S, Kadia T, Borthakur G, Estrov Z, Jabbour E, Faderl S, Ravandi F, Cortes J, Tefferi A, Kantarjian H, Garcia-Manero G. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol 88(5):365-9, 5/2013. e-Pub 3/20/2013. PMID: 23512829.
3. Sokol L, Cripe L, Kantarjian H, Sekeres MA, Parmar S, Greenberg P, Goldberg SL, Bhushan V, Shammo J, Hohl R, Verma A, Garcia-Manero G, Li YP, Lowe A, Zhu J, List AF. Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome. Leukemia 27(4):977-80, 4/2013. e-Pub 9/11/2012. PMID: 23032694.
4. Wei Y, Chen R, Dimicoli S, Bueso-Ramos C, Neuberg D, Pierce S, Wang H, Yang H, Jia Y, Zheng H, Fang Z, Nguyen M, Ganan-Gomez I, Ebert B, Levine R, Kantarjian H, Garcia-Manero G. Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells. Leukemia. e-Pub 3/29/2013. PMID: 23538751.
5. Greenberg PL, Garcia-Manero G, Moore M, Damon L, Roboz G, Hu K, Yang AS, Franklin J. A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome (MDS) receiving decitabine. Leuk Lymphoma 54(2):321-8, 2/2013. e-Pub 11/15/2012. PMID: 22906162.
6. Borthakur G, Rosenblum MG, Talpaz M, Daver N, Ravandi F, Faderl S, Freireich EJ, Kadia T, Garcia-Manero G, Kantarjian H, Cortes JE. Phase 1 study of anti-CD33 immunotoxin HUM-195/rGEL in patients withadvanced myeloid malignancies. Haematologica 98(2):217-21, 2/2013. e-Pub 8/8/2012. PMCID: PMC3561428.
7. Oran B, Popat U, Rondon G, Ravandi F, Garcia-Manero G, Abruzzo L, Andersson BS, Bashir Q, Chen J, Kebriaei P, Khouri IF, Koca E, Qazilbash MH, Champlin R, de Lima M. Significance of Persistent Cytogenetic Abnormalities at Myeloablative Allogeneic Stem Cell Transplantation in First Complete Remission. Biol Blood Marrow Transplant 19(2):214-20, 2/2013. e-Pub 9/13/2012. PMID: 22982533.
8. Daver N, Strati P, Jabbour E, Kadia T, Luthra R, Wang S, Patel K, Ravandi F, Cortes J, Qin Dong X, Kantarjian H, Garcia-Manero G. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol 88(1):56-9, 1/2013. e-Pub 10/31/2012. PMID: 23115106.
9. Quintás-Cardama A, Ravandi F, Liu-Dumlao T, Brandt M, Faderl S, Pierce S, Borthakur G, Garcia-Manero G, Cortes J, Kantarjian H. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood 120(24):4840-5, 12/6/2012. e-Pub 10/15/2012. PMID: 23071272.
10. Kadia TM, Kantarjian H, Kornblau S, Borthakur G, Faderl S, Freireich EJ, Luthra R, Garcia-Manero G, Pierce S, Cortes J, Ravandi F. Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. Cancer 118(22):5550-9, 11/15/2012. e-Pub 5/8/2012. PMCID: PMC3416961.
11. Boumber Y, Kantarjian H, Jorgensen J, Wen S, Faderl S, Castoro R, Autry J, Garcia-Manero G, Borthakur G, Jabbour E, Estrov Z, Cortes J, Issa JP, Ravandi F. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia 26(11):2428-31, 11/2012. e-Pub 6/5/2012. PMID: 22665218.
12. Takahashi K, Yabe M, Shapira I, Pierce S, Garcia-Manero G, Varma M. Clinical and cytogenetic characteristics of myelodysplastic syndrome in patients with HIV infection. Leuk Res 36(11):1376-9, 11/2012. e-Pub 8/21/2012. PMID: 22917767.
13. Kantarjian H, Faderl S, Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Coutre S, Stock W, Claxton D, Goldberg SL, Arellano M, Strickland SA, Seiter K, Schiller G, Jabbour E, Chiao J, Plunkett W. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol 13(11):1096-104, 11/2012. e-Pub 10/15/2012. PMID: 23075701.
14. Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer 118(18):4471-7, 9/15/2012. e-Pub 1/26/2012. PMID: 22282348.
15. Strom SS, Oum R, Elhor Gbito KY, Garcia-Manero G, Yamamura Y. De novo acute myeloid leukemia risk factors: A Texas case-control study. Cancer 118(18):4589-96, 9/15/2012. e-Pub 2/1/2012. PMID: 22297571.
16. Dey A, Seshasayee D, Noubade R, French DM, Liu J, Chaurushiya MS, Kirkpatrick DS, Pham VC, Lill JR, Bakalarski CE, Wu J, Phu L, Katavolos P, LaFave LM, Abdel-Wahab O, Modrusan Z, Seshagiri S, Dong K, Lin Z, Balazs M, Suriben R, Newton K, Hymowitz S, Garcia-Manero G, Martin F, Levine RL, Dixit VM. Loss of the tumor suppressor BAP1 causes myeloid transformation. Science 337(6101):1541-6, 9/21/2012. e-Pub 8/9/2012. PMID: 22878500.
17. Tong WG, Quintás-Cardama A, Kadia T, Borthakur G, Jabbour E, Ravandi F, Faderl S, Wierda W, Pierce S, Shan J, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Predicting survival of patients with hypocellular myelodysplastic syndrome: Development of a disease-specific prognostic score system. Cancer 118(18):4462-70, 9/15/2012. e-Pub 1/17/2012. PMID: 22252728.
18. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D. Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes. Blood 120(12):2454-65, 9/20/2012. e-Pub 6/27/2012. PMID: 22740453.
19. Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N, Raza A, Kantarjian H, Levine RL, Neuberg D, Garcia-Manero G, Ebert BL. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 30(27):3376-82, 9/20/2012. e-Pub 8/6/2012. PMCID: PMC3438234.
20. Sikkema AH, den Dunnen WF, Hulleman E, van Vuurden DG, Garcia-Manero G, Yang H, Scherpen FJ, Kampen KR, Hoving EW, Kamps WA, Diks SH, Peppelenbosch MP, de Bont ES. EphB2 activity plays a pivotal role in pediatric medulloblastoma cell adhesion and invasion. Neuro Oncol 14(9):1125-35, 9/2012. e-Pub 6/21/2012. PMCID: PMC3424207.
21. Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X, Chen SC, Payne-Turner D, Churchman ML, Harvey RC, Chen X, Kasap C, Yan C, Becksfort J, Finney RP, Teachey DT, Maude SL, Tse K, Moore R, Jones S, Mungall K, Birol I, Edmonson MN, Hu Y, Buetow KE, Chen IM, Carroll WL, Wei L, Ma J, Kleppe M, Levine RL, Garcia-Manero G, Larsen E, Shah NP, Devidas M, Reaman G, Smith M, Paugh SW, Evans WE, Grupp SA, Jeha S, Pui CH, Gerhard DS, Downing JR, Willman CL, Loh M, Hunger SP, Marra MA, Mullighan CG. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 22(2):153-66, 8/14/2012. PMCID: PMC3422513.
22. Tang G, Jorgensen JL, Zhou Y, Hu Y, Kersh M, Garcia-Manero G, Jeffrey Medeiros L, Wang SA. Multi-color CD34(+) progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post cancer therapy cytopenia. Leuk Res 36(8):974-81, 8/2012. e-Pub 5/23/2012. PMID: 22626984.
23. Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H. Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 12(4):244-51, 8/2012. e-Pub 4/24/2012. PMID: 22534616.
24. Khoury HJ, Garcia-Manero G, Borthakur G, Kadia T, Foudray MC, Arellano M, Langston A, Bethelmie-Bryan B, Rush S, Litwiler K, Karan S, Simmons H, Marcus AI, Ptaszynski M, Kantarjian H. A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias. Cancer 118(14):3556-64, 7/15/2012. e-Pub 12/2/2011. PMID: 22139909.
25. Nardi V, Winkfield KM, Ok CY, Niemierko A, Kluk MJ, Attar EC, Garcia-Manero G, Wang SA, Hasserjian RP. Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. J Clin Oncol 30(19):2340-7, 7/1/2012. e-Pub 5/14/2012. PMID: 22585703.
26. Garcia-Manero G. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 87(7):692-701, 7/2012. PMID: 22696212.
27. Kanagal-Shamanna R, Bueso-Ramos CE, Barkoh B, Lu G, Wang S, Garcia-Manero G, Vadhan-Raj S, Hoehn D, Medeiros LJ, Yin CC. Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53. Cancer 118(11):2879-88, 6/1/2012. e-Pub 10/28/2011. PMID: 22038701.
28. Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, Borthakur G, Kadia TM, Konopleva MY, Faderl S, Cortes JE, Brandt M, Hu Y, McCue D, Newsome WM, Pierce SR, de Lima M, Kantarjian HM. Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. J Clin Oncol 30(18):2204-10, 6/20/2012. e-Pub 5/14/2012. PMID: 22585696.
29. Kantarjian HM, Padmanabhan S, Stock W, Tallman MS, Curt GA, Li J, Osmukhina A, Wu K, Huszar D, Borthukar G, Faderl S, Garcia-Manero G, Kadia T, Sankhala K, Odenike O, Altman JK, Minden M. Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia. Invest New Drugs 30(3):1107-15, 6/2012. e-Pub 4/15/2011. PMID: 21494838.
30. Lu H, Marengo MF, Mihu CN, Garcia-Manero G, Suarez-Almazor ME. Rare Case of Septic Arthritis Caused by Candida krusei: Case Report and Literature Review. J Rheumatol 39(6):1308-9, 6/2012. PMID: 22661427.
31. Sampath D, Garcia-Manero G. Therapy for older patients with acute myeloblastic leukemia: a problem in search of a solution. Leuk Lymphoma 53(6):1013-4, 6/2012. PMID: 22506546.
32. Kantarjian H, O'Brien S, Garcia-Manero G, Faderl S, Ravandi F, Jabbour E, Shan J, Cortes J. Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy. Cancer 118(12):3116-22, 6/2012. e-Pub 2/2012. PMCID: PMC3370116.
33. Jabbour E, Cortes J, Nazha A, O'Brien S, Quintas-Cardama A, Pierce S, Garcia-Manero G, Kantarjian H. EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Blood 119(19):4524-6, 5/10/2012. e-Pub 3/19/2012. PMCID: PMC3362365.
34. Ravandi F, Patel K, Luthra R, Faderl S, Konopleva M, Kadia T, Brandt M, Pierce S, Kornblau S, Andreeff M, Wang X, Garcia-Manero G, Cortes J, Kantarjian H. Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Cancer 118(10):2665-73, 5/15/2012. e-Pub 10/21/2011. PMID: 22020636.
35. Kadia TM, Borthakur G, Garcia-Manero G, Faderl S, Jabbour E, Estrov Z, York S, Huang X, Pierce S, Brandt M, Koller C, Kantarjian HM, Ravandi F. Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol 157(3):312-20, 5/2012. e-Pub 2/2012. PMID: 22360602.
36. Zage PE, Nolo R, Fang W, Stewart J, Garcia-Manero G, Zweidler-McKay PA. Notch pathway activation induces neuroblastoma tumor cell growth arrest. Pediatr Blood Cancer 58(5):682-9, 5/2012. e-Pub 7/8/2011. PMCID: PMC3264695.
37. Kantarjian H, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S, Kadia T, Borthakur G, Huang X, Champlin R, Talpaz M, Cortes J. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 119(9):1981-7, 3/1/2012. e-Pub 1/6/2012. PMCID: PMC3311242.
38. Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Garcia-Manero G, Faderl S, Pierce S, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D. New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge. J Clin Oncol 30(8):820-9, 3/10/2012. e-Pub 2/13/2012. PMID: 22331955.
39. Eghtedar A, Borthakur G, Ravandi F, Jabbour E, Cortes J, Pierce S, Kantarjian H, Garcia-Manero G. Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia. Am J Hematol 87(3):317-8, 3/2012. e-Pub 1/2012. PMID: 22228403.
40. Faderl S, Garcia-Manero G, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Gandhi V, Byrd AL, Kwari M, Cortes J, Kantarjian HM. A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer 118(3):722-8, 2/1/2012. e-Pub 7/12/2011. PMID: 21751197.
41. Hu Y, Lu W, Chen G, Wang P, Chen Z, Zhou Y, Ogasawara M, Trachootham D, Feng L, Pelicano H, Chiao PJ, Keating MJ, Garcia-Manero G, Huang P. K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Res 22(2):399-412, 2/2012. e-Pub 8/30/2011. PMCID: PMC3257361.
42. Patnaik MM, Lasho TL, Hodnefield JM, Knudson RA, Ketterling RP, Garcia-Manero G, Steensma DP, Pardanani A, Hanson CA, Tefferi A. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 119(2):569-72, 1/12/2012. e-Pub 11/17/2011. PMID: 22096241.
43. Dimicoli S, Jabbour E, Borthakur G, Kadia T, Estrov Z, Yang H, Kelly M, Pierce S, Kantarjian H, Garcia-Manero G. Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. Am J Hematol 87(1):127-9, 1/2012. e-Pub 11/2011. PMID: 22072492.
44. Raza A, Galili N, Mulford D, Smith SE, Brown GL, Steensma DP, Lyons RM, Boccia R, Sekeres MA, Garcia-Manero G, Mesa RA. Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS). J Hematol Oncol 5:18, 2012. e-Pub 4/2012. PMCID: PMC3416694.
45. Jabbour E, Kantarjian HM, O'Brien S, Shan J, Quintás-Cardama A, Garcia-Manero G, Rios MB, Cortes JE. Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response? J Clin Oncol 29(32):4260-5, 11/10/2011. e-Pub 10/11/2011. PMCID: PMC3221527.
46. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller CA, Burger JA, Lerner S, Schlette E, Abruzzo L, Kantarjian HM, Keating MJ. Multivariable Model for Time to First Treatment in Patients With Chronic Lymphocytic Leukemia. J Clin Oncol 29(31):4088-95, 11/1/2011. e-Pub 10/3/2011. PMID: 21969505.
47. Quintás-Cardama A, Kantarjian H, Shan J, Jabbour E, Abruzzo LV, Verstovsek S, Garcia-Manero G, O'Brien S, Cortes J. Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib. Cancer 117(22):5085-93, 11/15/2011. e-Pub 4/26/2011. PMID: 21523765.
48. Wood SM, Meyers CA, Faderl S, Kantarjian HM, Pierce SA, Garcia-Manero G. Association of anemia and cognitive dysfunction in patients with acute myelogenous leukemia and myelodysplastic syndrome. Am J Hematol 86(11):950-2, 11/2011. e-Pub 9/14/2011. PMID: 21919036.
49. Naqvi K, Jabbour E, Bueso-Ramos C, Pierce S, Borthakur G, Estrov Z, Ravandi F, Faderl S, Kantarjian H, Garcia-Manero G. Implications of discrepancy in morphological diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood 118(17):4690-3, 10/27/2011. e-Pub 8/25/2011. PMID: 21868570.
50. Jabbour E, Kantarjian H, O'Brien S, Shan J, Quintas-Cardama A, Faderl S, Garcia-Manero G, Ravandi F, Rios MB, Cortes J. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 118(17):4541-6; quiz 4759, 10/27/2011. e-Pub 7/29/2011. PMCID: PMC3291489.
51. De Yao JT, Al-Ameri A, Garcia-Manero G, Quintás-Cardama A. Infrequent Presentations of Mucormycosis in Patients With Myelodysplastic Syndrome and Acute Leukemia: Case Series and Review of Literature. Clin Lymphoma Myeloma Leuk 11(5):446-51, 10/2011. e-Pub 8/5/2011. PMID: 21820986.
52. Garcia-Manero G. Integrating care for patients with lower risk myelodysplastic syndrome. Semin Oncol 38(5):658-66, 10/2011. PMID: 21943672.
53. Garcia-Manero G. Introduction: advances in myelodysplastic syndromes. Semin Oncol 38(5):612, 10/2011. PMID: 21943666.
54. Cortes J, Quintas-Cardama A, Jabbour E, O'Brien S, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Burton E, Shan J, Kantarjian H. The Clinical Significance of Achieving Different Levels of Cytogenetic Response in Patients With Chronic Phase Chronic Myeloid Leukemia After Failure to Front-Line Therapy: Is Complete Cytogenetic Response the Only Desirable Endpoint? Clin Lymphoma Myeloma Leuk 11(5):421-6, 10/2011. e-Pub 8/10/2011. PMCID: PMC3215673.
55. Garcia-Manero G. Treatment of higher-risk myelodysplastic syndrome. Semin Oncol 38(5):673-81, 10/2011. PMID: 21943674.
56. Kantarjian H, O'Brien S, Jabbour E, Shan J, Ravandi F, Kadia T, Faderl S, Garcia-Manero G, Borthakur G, Cortes J. Impact of Treatment End Point Definitions on Perceived Differences in Long-Term Outcome With Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia. J Clin Oncol 29(23):3173-8, 8/10/2011. e-Pub 7/11/2011. PMID: 21747082.
57. Al-Ameri A, Cherry M, Garcia-Manero G, Quintás-Cardama A. Standard therapy for patients with myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk 11(4):303-13, 8/2011. PMID: 21816368.
58. Zuo Z, Calin GA, de Paula HM, Medeiros LJ, Fernandez MH, Shimizu M, Garcia-Manero G, Bueso-Ramos CE. Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome. Blood 118(2):413-5, 7/14/2011. e-Pub 5/20/2011. PMCID: PMC3293748.
59. Dayyani F, Mougalian SS, Naqvi K, Shan J, Ravandi F, Cortes J, Weinberg J, Jabbour E, Faderl S, Wierda W, Thomas D, O'Brien S, Pierce S, Kantarjian H, Garcia-Manero G. Prediction model for mortality after intracranial hemorrhage in patients with leukemia. Am J Hematol 86(7):546-9, 7/2011. e-Pub 4/20/2011. PMID: 21509801.
60. Naqvi K, Garcia-Manero G, Sardesai S, Oh J, Vigil CE, Pierce S, Lei X, Shan J, Kantarjian HM, Suarez-Almazor ME. Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. J Clin Oncol 29(16):2240-6, 6/1/2011. e-Pub 5/2/2011. PMCID: PMC3107743.
61. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D, Ebert BL. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364(26):2496-506, 6/30/2011. PMCID: PMC3159042.
62. Chen Y, Cortes J, Estrov Z, Faderl S, Qiao W, Abruzzo L, Garcia-Manero G, Pierce S, Huang X, Kebriaei P, Kadia T, De Lima M, Kantarjian H, Ravandi F. Persistence of Cytogenetic Abnormalities at Complete Remission After Induction in Patients With Acute Myeloid Leukemia: Prognostic Significance and the Potential Role of Allogeneic Stem-Cell Transplantation. J Clin Oncol 29(18):2507-13, 6/20/2011. e-Pub 5/9/2011. PMID: 21555694.
63. Garcia-Manero G, Gore SD, Cogle C, Ward R, Shi T, Macbeth KJ, Laille E, Giordano H, Sakoian S, Jabbour E, Kantarjian H, Skikne B. Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia. J Clin Oncol 29(18):2521-7, 6/20/2011. e-Pub 5/16/2011. PMID: 21576646.
64. Mallo M, Luño E, Sanzo C, Cervera J, Haase D, Schanz J, García-Manero G, del Cañizo C, Sanz GF, Solé F. Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome. Leuk Res 35(6):834-6, 6/2011. e-Pub 1/26/2011. PMID: 21269692.
65. Boumber Y, Younes A, Garcia-Manero G. Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor. Expert Opin Investig Drugs 20(6):823-9, 6/2011. e-Pub 5/10/2011. PMID: 21554162.
66. Garcia-Manero G. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 86(6):490-8, 6/2011. PMID: 21594886.
67. Schanz J, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Tuechler H, Valent P, Hildebrandt B, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Garcia-Manero G, Kantarjian H, Germing U, Haase D, Estey E. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol 29(15):1963-70, 5/20/2011. e-Pub 4/25/2011. PMID: 21519021.
68. Bryan J, Kantarjian H, Garcia-Manero G, Jabbour E. Pharmacokinetic evaluation of decitabine for the treatment of leukemia. Expert Opin Drug Metab Toxicol 7(5):661-72, 5/2011. e-Pub 4/2011. PMID: 21500965.
69. Wei Y, Gañán-Gómez I, Salazar-Dimicoli S, McCay SL, Garcia-Manero G. Histone methylation in myelodysplastic syndromes. Epigenomics 3(2):193-205, 4/2011. PMID: 22122281.
70. Al Ameri A, Jabbour E, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Shan J, Pierce S, Cortes J, Kantarjian H. Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications. Clin Lymphoma Myeloma Leuk 11(2):237-41, 4/2011. e-Pub 4/8/2011. PMID: 21575929.
71. Jabbour E, Kantarjian H, Ravandi F, Garcia-Manero G, Estrov Z, Verstovsek S, O'Brien S, Faderl S, Thomas DA, Wright JJ, Cortes J. A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 117(6):1236-44, 3/15/2011. e-Pub 10/19/2010. PMID: 20960519.
72. Wang SA, Abruzzo LV, Hasserjian RP, Zhang L, Hu Y, Zhang Y, Zhao M, Galili N, Raza A, Medeiros LJ, Garcia-Manero G, Miranda RN. Myelodysplastic syndromes with deletions of chromosome 11q lack cryptic MLL rearrangement and exhibit characteristic clinicopathologic features. Leuk Res 35(3):351-7, 3/2011. e-Pub 8/5/2010. PMID: 20691474.
73. Santos FP, Kantarjian H, Garcia-Manero G, Ravandi F. The Search for Better Prognostic Models in Myelodysplastic Syndromes. Curr Hematol Malig Rep 6(1):13-21, 3/2011. e-Pub 12/7/2010. PMID: 21136214.
74. Garcia-Manero G, Fenaux P. Hypomethylating Agents and Other Novel Strategies in Myelodysplastic Syndromes. J Clin Oncol 29(5):516-23, 2/10/2011. e-Pub 1/10/2011. PMCID: PMC3056493.
75. Cortes J, Quintás-Cardama A, Jones D, Ravandi F, Garcia-Manero G, Verstovsek S, Koller C, Hiteshew J, Shan J, O'Brien S, Kantarjian H. Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. Cancer 117(3):572-80, 2/1/2011. e-Pub 9/30/2010. PMID: 20886606.
76. Jabbour E, Kantarjian H, O'Brien S, Shan J, Garcia-Manero G, Wierda W, Ravandi F, Borthakur G, Rios MB, Cortes J. Predictive factors for outcome and response in patients treated with second generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase post imatinib failure. Blood 117(6):1822-7, 2/10/2011. e-Pub 10/28/2010. PMID: 21030554.
77. Faderl S, Thomas DA, O'Brien S, Ravandi F, Garcia-Manero G, Borthakur G, Ferrajoli A, Verstovsek S, Ayoubi M, Rytting M, Feliu J, Kantarjian HM. Augmented Hyper-CVAD Based on Dose-Intensified Vincristine, Dexamethasone, and Asparaginase in Adult Acute Lymphoblastic Leukemia Salvage Therapy. Clin Lymphoma Myeloma Leuk 11(1):54-9, 2/2011. PMID: 21454191.
78. Quintás-Cardama A, Santos FP, Garcia-Manero G. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia 25(2):226-35, 2/2011. e-Pub 11/30/2010. PMID: 21116282.
79. Yang H, Fang Z, Wei Y, Hu Y, Calin GA, Kantarjian HM, Garcia-Manero G. Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA. Am J Hematol 86(2):237-8, 2/2011. PMID: 21264920.
80. Dayyani F, Kantarjian H, O'Brien S, Pierce S, Jones D, Faderl S, Garcia-Manero G, Cortes J, Ravandi F. Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. Cancer 117(1):110-5, 1/1/2011. e-Pub 8/27/2010. PMID: 20803607.
81. Mallo M, Cervera J, Schanz J, Such E, García-Manero G, Luño E, Steidl C, Espinet B, Vallespí T, Germing U, Blum S, Ohyashiki K, Grau J, Pfeilstöcker M, Hernández JM, Noesslinger T, Giagounidis A, Aul C, Calasanz MJ, Martín ML, Valent P, Collado R, Haferlach C, Fonatsch C, Lübbert M, Stauder R, Hildebrandt B, Krieger O, Pedro C, Arenillas L, Sanz MÁ, Valencia A, Florensa L, Sanz GF, Haase D, Solé F. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia 25(1):110-20, 1/2011. e-Pub 9/30/2010. PMID: 20882045.
82. Garcia-Manero G. Nontransplantation options for patients with myelodysplastic syndromes. Biol Blood Marrow Transplant 17(1 Suppl):S9-10, 1/2011. PMID: 21195318.
83. Ravandi F, Cortes J, Faderl S, O'Brien S, Garcia-Manero G, Verstovsek S, Santos FP, Shan J, Brandt M, de Lima M, Pierce S, Kantarjian H. Characteristics and outcome of patients with acute myeloid leukemia refractory to one cycle of high dose cytarabine-based induction chemotherapy. Blood 116(26):5818-23; quiz 6153, 12/23/2010. e-Pub 10/5/2010. PMID: 20923968.
84. Kantarjian HM, Thomas D, Ravandi F, Faderl S, Jabbour E, Garcia-Manero G, Pierce S, Shan J, Cortes J, O'Brien S. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer 116(24):5568-74, 12/15/2010. e-Pub 8/24/2010. PMID: 20737576.
85. de Lima M, Giralt S, Thall PF, de Padua Silva L, Jones RB, Komanduri K, Braun TM, Nguyen HQ, Champlin R, Garcia-Manero G. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 116(23):5420-31, 12/1/2010. e-Pub 7/29/2010. PMID: 20672358.
86. Kantarjian H, Ravandi F, O'Brien S, Cortes J, Faderl S, Garcia-Manero G, Jabbour E, Wierda W, Kadia T, Pierce S, Shan J, Keating M, Freireich EJ. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 116(22):4422-9, 11/25/2010. e-Pub 7/28/2010. PMID: 20668231.
87. Rytting M, Ravandi F, Estey E, Cortes J, Faderl S, Garcia-Manero G, Jeha S, Ouzounian S, Pierce S, Kantarjian H. Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study. Cancer 116(22):5272-8, 11/15/2010. e-Pub 7/21/2010. PMID: 20665501.
88. Hu Y, Lu W, Chen G, Zhang H, Jia Y, Wei Y, Yang H, Zhang W, Fiskus W, Bhalla K, Keating M, Huang P, Garcia-Manero G. Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound {beta}-phenylethyl isothiocyanate. Blood 116(15):2732-41, 10/14/2010. e-Pub 6/21/2010. PMID: 20566897.
89. Kantarjian HM, Giles FJ, Greenberg PL, Paquette RL, Wang ES, Gabrilove JL, Garcia-Manero G, Hu K, Franklin JL, Berger DP. Phase II study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood 116(17):3163-70, 10/28/2010. e-Pub 7/14/2010. PMID: 20631375.
90. Wei Y, Kadia T, Tong W, Zhang M, Jia Y, Yang H, Hu Y, Viallet J, O'Brien S, Garcia-Manero G. The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Autophagy 6(7):976-8, 10/1/2010. e-Pub 10/23/2010. PMID: 20729640.
91. Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R, Dara S, Jorgensen J, Kebriaei P, Champlin R, Borthakur G, Burger J, Ferrajoli A, Garcia-Manero G, Wierda W, Cortes J, Kantarjian H. First report of phase II study of dasatinib with hyperCVAD for the frontline treatment of patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia. Blood 116(12):2070-7, 9/23/2010. e-Pub 5/13/2010. PMID: 20466853.
92. Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Ravandi F, Verstovsek S, Jorgensen JL, Bueso-Ramos C, Andreeff M, Pierce S, Garris R, Keating MJ, Cortes J, Kantarjian HM. Chemoimmunotherapy With a Modified Hyper-CVADand Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome-Negative Precursor B-Lineage Acute Lymphoblastic Leukemia. J Clin Oncol 28(24):3880-9, 8/20/2010. e-Pub 7/26/2010. PMCID: PMC2940403.
93. Jabbour E, Garcia-Manero G, Batty N, Shan J, O'Brien S, Cortes J, Ravandi F, Issa JP, Kantarjian H. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer 116(16):3830-4, 8/15/2010. PMID: 20564137.
94. Wei Y, Kadia T, Tong W, Zhang M, Jia Y, Yang H, Hu Y, Tambaro FP, Viallet J, O'Brien S, Garcia-Manero G. The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Clin Cancer Res 16(15):3923-32, 8/1/2010. e-Pub 6/10/2010. PMID: 20538760.
95. Santos FP, Kantarjian H, Fava C, O'Brien S, Garcia-Manero G, Ravandi F, Wierda W, Thomas D, Shan J, Cortes J. Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Br J Haematol 150(3):303-12, 8/2010. e-Pub 6/10/2010. PMID: 20553275.
96. Tong WG, Wierda WG, Lin E, Kuang SQ, Bekele BN, Estrov Z, Wei Y, Yang H, Keating MJ, Garcia-Manero G. Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. Epigenetics 5(6):499-508, 8/2010. e-Pub 8/2010. PMID: 20484983.
97. Bashir Q, De Lima MJ, McMannis JD, Garcia-Manero G, Shpall E, Kantarjian H, Cortes JE, O'Brien SM, Jones D, Qazilbash M, Wei W, Giralt SA, Champlin RE, Hosing C. Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. Leuk Lymphoma 51(8):1478-84, 8/2010. PMID: 20658954.
98. Quintás-Cardama A, Santos FP, Garcia-Manero G. Therapy with azanucleosides for myelodysplastic syndromes. Nat Rev Clin Oncol 7(8):433-44, 8/2010. e-Pub 6/2010. PMID: 20551943.
99. Bryan J, Jabbour E, Prescott H, Garcia-Manero G, Issa JP, Kantarjian H. Current and future management options for myelodysplastic syndromes. Drugs 70(11):1381-94, 7/30/2010. PMID: 20614946.
100. Kadia TM, Yang H, Ferrajoli A, Maddipotti S, Schroeder C, Madden TL, Holleran JL, Egorin MJ, Ravandi F, Thomas DA, Newsome W, Sanchez-Gonzalez B, Zwiebel JA, Espinoza-Delgado I, Kantarjian HM, Garcia-Manero G. A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Br J Haematol 150(1):72-82, 7/2010. e-Pub 4/29/2010. PMID: 20456355.
101. Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Borthakur G, Cortes JE, O'Brien S, Gandhi V, Plunkett W, Byrd A, Kwari M, Kantarjian HM. Oral Clofarabine in the Treatment of Patients With Higher-Risk Myelodysplastic Syndrome. J Clin Oncol 28(16):2755-60, 6/1/2010. e-Pub 4/26/2010. PMID: 20421540.
102. Verma D, Kantarjian H, Shan J, O'Brien S, Estrov Z, Garcia-Manero G, Koller C, Borthakur G, Cortes J. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer 116(11):2673-81, 6/1/2010. PMID: 20499401.
103. Batty GN, Kantarjian H, Issa JP, Jabbour E, Santos FP, McCue D, Garcia-Manero G, Pierce S, O'Brien S, Cortés JE, Ravandi F. Feasibility of therapy with hypomethylating agents in patients with renal insufficiency. Clin Lymphoma Myeloma Leuk 10(3):205-10, 6/2010. PMID: 20511166.
104. Shi P, Chandra J, Sun X, Gergely M, Cortes JE, Garcia-Manero G, Arlinghaus RB, Lai R, Amin HM. Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukemia cells. J Cell Mol Med 14(6B):1777-92, 6/2010. e-Pub 6/5/2009. PMID: 19508387.
105. Ravandi F, Kantarjian H, Faderl S, Garcia-Manero G, O'Brien S, Koller C, Pierce S, Brandt M, Kennedy D, Cortes J, Beran M. Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leuk Res 34(6):752-6, 6/2010. e-Pub 10/29/2009. PMID: 19878996.
106. Garcia-Manero G. Update on treatments for patients with myelodysplastic syndrome. Clin Adv Hematol Oncol 8(6):407-9, 6/2010. PMID: 20733550.
107. Dayyani F, Conley AP, Strom SS, Stevenson W, Cortes JE, Borthakur G, Faderl S, O'Brien S, Pierce S, Kantarjian H, Garcia-Manero G. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer 116(9):2174-9, 5/1/2010. e-Pub 2/2010. PMID: 20162709.
108. Sampat K, Rossi A, Garcia-Gutierrez V, Cortes J, Pierce S, Kantarjian H, Garcia-Manero G. Characteristics of pericardial effusions in patients with leukemia. Cancer 116(10):2366-71, 5/15/2010. e-Pub 3/2010. PMID: 20209609.
109. Chandra P, Luthra R, Zuo Z, Yao H, Ravandi F, Reddy N, Garcia-Manero G, Kantarjian H, Jones D. Acute myeloid leukemia with t(9;11)(p21-22;q23): common properties of dysregulated ras pathway signaling and genomic progression characterize de novo and therapy-related cases. Am J Clin Pathol 133(5):686-93, 5/2010. PMID: 20395514.
110. Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce SR, Brandt M, Byrd A, Bekele BN, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian HM. Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia. J Clin Oncol 28(11):1856-62, 4/10/2010. e-Pub 3/8/2010. PMCID: PMC2930809.
111. Strom SS, Estey E, Outschoorn UM, Garcia-Manero G. Acute myeloid leukemia outcome: role of nucleotide excision repair polymorphisms in intermediate risk patients. Leuk Lymphoma 51(4):598-605, 4/2010. e-Pub 2/2010. PMCID: PMC2918264.
112. Wang SA, Jabbar K, Lu G, Chen SS, Galili N, Vega F, Jones D, Raza A, Kantarjian H, Garcia-Manero G, McDonnell TJ, Medeiros LJ. Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features. Leukemia 24(4):740-7, 4/2010. e-Pub 1/14/2010. PMID: 20072149.
113. Kuang SQ, Bai H, Fang ZH, Lopez G, Yang H, Tong W, Wang ZZ, Garcia-Manero G. Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia. Blood 115(12):2412-9, 3/25/2010. e-Pub 1/8/2010. PMCID: PMC2845899.
114. Kantarjian HM, Thomas D, Ravandi F, Faderl S, Garcia-Manero G, Shan J, Pierce S, Cortes J, O'Brien S. Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission. Leuk Lymphoma 51(3):475-480, 3/2010. e-Pub 1/18/2010. PMID: 20078325.
115. Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G, Kennedy D, Estrov Z, Cortes J, Verstovsek S. Phase II study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post polycythemia vera/essential thrombocythemia myelofibrosis. Blood 115(6):1131-6, 2/11/2010. e-Pub 12/11/2009. PMID: 20008298.
116. Alatrash G, Albitar M, O'Brien S, Wang X, Manshouri T, Faderl S, Ferrajoli A, Burger J, Garcia-Manero G, Kantarjian HM, Lerner S, Keating MJ, Wierda WG. Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). Br J Haematol 148(3):386-93, 2/2010. e-Pub 11/6/2009. PMID: 19895616.
117. Jones D, Yao H, Romans A, Dando C, Pierce S, Borthakur G, Hamilton A, Bueso-Ramos C, Ravandi F, Garcia-Manero G, Kantarjian H. Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias. Genes Chromosomes Cancer 49(2):182-91, 2/2010. e-Pub 11/2009. PMID: 19908318.
118. Tong WG, Wei Y, Stevenson W, Kuang SQ, Fang Z, Zhang M, Arts J, Garcia-Manero G. Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor. Leuk Res 34(2):221-8, 2/2010. e-Pub 8/13/2009. PMID: 19682743.
119. Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Westwood R, Green SR, Chiao JH, Boone PA, Cortes J, Plunkett W. Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. J Clin Oncol 28(2):285-91, 1/10/2010. e-Pub 11/23/2009. PMID: 19933907.
120. Santos FP, Kantarjian H, Garcia-Manero G, Issa JP, Ravandi F. Decitabine in the treatment of myelodysplastic syndromes. Expert Rev Anticancer Ther 10(1):9-22, 1/2010. PMID: 20014881.
121. Garcia-Manero G. Prognosis of myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2010:330-7, 2010. PMID: 21239815.
122. Vigil CE, Martin-Santos T, Garcia-Manero G. Safety and efficacy of azacitidine in myelodysplastic syndromes. Drug Des Devel Ther 4:221-9, 2010. e-Pub 9/24/2010. PMCID: PMC2948932.
123. Ma W, Kantarjian H, Zhang K, Zhang X, Wang X, Chen C, Donahue AC, Zhang Z, Yeh CH, O'Brien S, Garcia-Manero G, Caporaso N, Landgren O, Albitar M. Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome. BMC Med Genet 11:163, 2010. e-Pub 11/16/2010. PMCID: PMC2992491.
124. Santos FP, Faderl S, Garcia-Manero G, Koller C, Beran M, O'Brien S, Pierce S, Freireich EJ, Huang X, Borthakur G, Bueso-Ramos C, de Lima M, Keating M, Cortes J, Kantarjian H, Ravandi F. Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution. Leukemia 23(12):2275-80, 12/2009. e-Pub 9/2009. PMID: 19741728.
125. Thomas DA, Kantarjian HM, Stock W, Heffner LT, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Pierce S, Lu B, Deitcher SR, O'Brien S. Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. Cancer 115(23):5490-8, 12/2009. e-Pub 8/2009. PMID: 19708032.
126. Ravandi F, Issa JP, Garcia-Manero G, O'Brien S, Pierce S, Shan J, Borthakur G, Verstovsek S, Faderl S, Cortes J, Kantarjian H. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer 115(24):5746-51, 12/2009. e-Pub 9/2009. PMCID: PMC2794953.
127. Kantarjian H, O'Brien S, Ravandi F, Borthakur G, Faderl S, Bueso-Ramos C, Abruzzo L, Pierce S, Shan J, Issa JP, Garcia-Manero G. The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS? Cancer 115(22):5202-9, 11/2009. e-Pub 8/2009. PMCID: PMC2783477.
128. Hoshino K, Quintás-Cardama A, Radich J, Dai H, Yang H, Garcia-Manero G. Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemia. Leuk Res 33(10):1361-6, 10/2009. e-Pub 5/2009. PMID: 19409613.
129. Quintás-Cardama A, Kantarjian HM, Manshouri T, Thomas D, Cortes J, Ravandi F, Garcia-Manero G, Ferrajoli A, Bueso-Ramos C, Verstovsek S. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 27(28):4760-6, 10/2009. e-Pub 8/2009. PMID: 19720904.
130. Choi SH, Worswick S, Byun HM, Shear T, Soussa JC, Wolff EM, Douer D, Garcia-Manero G, Liang G, Yang AS. Changes in DNA methylation of tandem DNA repeats are different from interspersed repeats in cancer. Int J Cancer 125(3):723-729, 8/2009. e-Pub 2/2009. PMID: 19437537.
131. Stone R, Sekeres M, Garcia-Manero G. Evolving strategies in the treatment of MDS and AML. Clin Adv Hematol Oncol 7(8):1-14; quiz 2 p following 14, 8/2009. PMID: 19927982.
132. Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia-Manero G, Albitar M, Larsen JS, Arora S, Cullen MT, Kantarjian H. Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial. J Clin Oncol 27(23):3842-8, 8/2009. e-Pub 6/2009. PMID: 19528372.
133. Alvarado Y, Kantarjian H, O'Brien S, Faderl S, Borthakur G, Burger J, Wierda W, Garcia-Manero G, Shan J, Cortes J. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 115(16):3709-3718, 8/2009. e-Pub 6/2009. PMID: 19517462.
134. Konoplev S, Huang X, Drabkin HA, Koeppen H, Jones D, Kantarjian HM, Garcia-Manero G, Chen W, Medeiros LJ, Bueso-Ramos CE. Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis. Cancer, 7/2009. e-Pub 7/2009. PMID: 19637342.
135. Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau MM, Beran M, Tallman MS, Ebert BL, Kantarjian HM, Stone RM, Gilliland DG, Crispino JD, Levine RL. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114(1):144-7, 7/2009. e-Pub 5/2009. PMID: 19420352.
136. Garg R, Faderl S, Garcia-Manero G, Cortes J, Koller C, Huang X, York S, Pierce S, Brandt M, Beran M, Borthakur G, Kantarjian H, Ravandi F.. Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Leukemia 23(7):1297-1302, 7/2009. e-Pub 2/2009. PMID: 19242494.
137. Lakshmikuttyamma A, Takahashi N, Pastural E, Torlakovic E, Amin HM, Garcia-Manero G, Voralia M, Czader M, Decoteau JF, Geyer CR. RIZ1 is potential CML tumor suppressor that is down-regulated during disease progression. J Hematol Oncol 2(1). e-Pub 7/2009. PMCID: PMC2719666.
138. De Padua Silva L, de Lima M, Kantarjian H, Faderl S, Kebriaei P, Giralt S, Davisson J, Garcia-Manero G, Champlin R, Issa JP, Ravandi F. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant 43(11):839-843, 6/2009. e-Pub 1/2009. PMID: 19151791.
139. Jain N, Cortes J, Quintás-Cardama A, Manshouri T, Luthra R, Garcia-Manero G, Kantarjian H, Verstovsek S. Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. Leuk Res 33(6):837-9, 6/2009. e-Pub 11/2008. PMID: 19013640.
140. Fava C, Kantarjian HM, Jabbour E, O'Brien S, Jain N, Rios MB, Garcia-Manero G, Ravandi F, Verstovsek S, Borthakur G, Shan J, Cortes J. Failure to achieve a complete hematologic response at the time of achievement of a major cytogenetic response with second generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood 113(21):5058-5063, 5/2009. e-Pub 3/2009. PMID: 19282457.
141. Jabbour E, Giralt S, Kantarjian H, Garcia-Manero G, Jagasia M, Kebriaei P, de Padua L, Shpall EJ, Champlin R, de Lima M.. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 115(9):1899-905, 5/2009. e-Pub 2/2009. PMID: 19235255.
142. Jabbour E, Garcia-Manero G, Taher A, Kantarjian HM. Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy. Oncologist 14(5):489-96, 5/2009. e-Pub 4/2009. PMID: 19365094.
143. Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL, Bass A, Marubayashi S, Heguy A, Garcia-Manero G, Kantarjian H, Offit K, Stone RM, Gilliland DG, Klein RJ, Levine RL. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 41(4):385-386, 4/2009. e-Pub 3/2009. PMID: 19287384.
144. Heinrichs S, Kulkarni RV, Bueso-Ramos CE, Levine RL, Loh ML, Li C, Neuberg D, Kornblau SM, Issa JP, Gilliland DG, Garcia-Manero G, Kantarjian HM, Estey EH, Look AT. Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia. e-Pub 4/2009. PMID: 19387468.
145. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do Ka, Garcia-Manero G, Cortes J, Thomas D, Koller C, Burger J, Lerner S, Kantarjian H, Keating M.. Characteristics Associated With Important Clinical End Points in Patients With Chronic Lymphocytic Leukemia at Initial Treatment. J Clin Oncol 27(10):1637-43, 4/2009. e-Pub 2/2009. PMID: 19224852.
146. Ye D, Garcia-Manero G, Kantarjian HM, Xiao L, Vadhan-Raj S, Fernandez MH, Nguyen MH, Medeiros LJ, Bueso-Ramos CE. Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia. J Hematop 2(1):2-8, 3/2009. e-Pub 11/2008. PMCID: PMC2713495.
147. Jabbour E, Kantarjian HM, Jones D, Shan J, O'Brien S, Reddy N, Wierda WG, Faderl S, Garcia-Manero G, Verstovsek S, Rios MB, Cortes J. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia post cytogenetic failure on standard-dose imatinib therapy. Blood 113(10):2154-2160, 3/2009. e-Pub 12/2008. PMID: 19060245.
148. Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H. Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin. J Clin Oncol 27(4):504-510, 2/2009. e-Pub 12/2008. PMID: 19075265.
149. Yang H, Kadia T, Xiao L, Bueso-Ramos CE, Hoshino K, Thomas DA, O'Brien S, Jabbour E, Pierce S, Rosner GL, Kantarjian HM, Garcia-Manero G. Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia. Blood 113(9):1892-8, 2/2009. e-Pub 12/2008. PMCID: PMC2651008.
150. Verma D, O'Brien S, Thomas D, Faderl S, Koller C, Pierce S, Kebriaei P, Garcia-Manero G, Cortes J, Kantarjian H, Ravandi F. Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens. Cancer 115(1):101-6, 1/2009. PMID: 19090005.
151. Garcia-Manero G. Progress in myelodysplastic syndromes. Clin Lymphoma Myeloma 9 Suppl 3:S286-92, 2009. PMID: 19778854.
152. Jabbour E, Kantarjian HM, Jones D, Reddy N, O'Brien S, Garcia-Manero G, Burger J, Cortes J. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 112(13):4839-4842, 12/2008. e-Pub 9/2008. PMID: 18818391.
153. O'Brien S, Thomas D, Ravandi F, Faderl S, Cortes J, Borthakur G, Pierce S, Garcia-Manero G, Kantarjian HM. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 113(11):3186-91, 12/2008. PMID: 18846563.
154. Gardner A, Mattiuzzi G, Faderl S, Borthakur G, Garcia-Manero G, Pierce S, Brandt M, Estey E. Randomized Comparison of Cooked and Noncooked Diets in Patients Undergoing Remission Induction Therapy for Acute Myeloid Leukemia. J Clin Oncol 26(35):5684-5688, 12/2008. e-Pub 10/2008. PMID: 18955453.
155. Stone R, Sekeres M, Garcia-Manero G, Lyons RM. Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy. Clin Adv Hematol Oncol 6(12):1-15, 12/2008. PMID: 19385003.
156. Borthakur G, Kantarjian H, Wang X, Plunkett WK, Gandhi VV, Faderl S, Garcia-Manero G, Ravandi F, Pierce S, Estey EH. Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. Cancer 113(11):3181-5, 12/2008. PMID: 18932257.
157. Yanada M, Borthakur G, Garcia-Manero G, Ravandi F, Faderl S, Pierce S, Kantarjian H, Estey E. Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia. Leuk Res 32(10):1505-9, 10/2008. e-Pub 4/2008. PMID: 18405972.
158. Greenberg PL, Attar E, Battiwalla M, Bennett JM, Bloomfield CD, DeCastro CM, Deeg HJ, Erba HP, Foran JM, Garcia-Manero G, Gore SD, Head D, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Saba HI, Shami PJ, Spiers K, Stone RM, Tallman MS, Westervelt P, Westervelt P. Myelodysplastic syndromes. J Natl Compr Canc Netw 6(9):902-26, 10/2008. PMID: 18926100.
159. Braiteh F, Soriano AO, Garcia-Manero G, Hong D, Johnson MM, Silva Lde P, Yang H, Alexander S, Wolff J, Kurzrock R. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res 14(19):6296-301, 10/2008. PMCID: PMC2582814.
160. Tam CS, Kantarjian H, Garcia-Manero G, Borthakur G, O'Brien S, Ravandi F, Shan J, Cortes J. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood 112(3):516-8, 8/1/2008. e-Pub 5/20/2008. PMID: 18492956.
161. Garcia-Manero G, Assouline S, Cortes J, Estrov Z, Kantarjian H, Yang H, Newsome WM, Miller WH, Rousseau C, Kalita A, Bonfils C, Dubay M, Patterson TA, Li Z, Besterman JM, Reid G, Laille E, Martell RE, Minden M. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 112(4):981-9, 8/2008. e-Pub 5/2008. PMID: 18495956.
162. Thomas DA, O'Brien S, Jorgensen JL, Cortes J, Faderl S, Garcia-Manero G, Verstovsek S, Koller C, Pierce S, Huh Y, Wierda W, Keating MJ, Kantarjian HM. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood 113(25). e-Pub 8/2008. PMID: 18703706.
163. Jabbour E, Kantarjian H, Jones D, Breeden M, Garcia-Manero G, O'Brien S, Ravandi F, Borthakur G, Cortes J. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 112(1):53-5, 7/2008. e-Pub 4/2008. PMID: 18403620.
164. Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett JM, List A, Fenaux P, Sanz G, Issa JP, Freireich EJ, Garcia-Manero G. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original international prognostic scoring system. Cancer 113(6):1351-61, 7/2008. PMID: 18618511.
165. Aribi A, Kantarjian H, Koller C, Thomas D, Faderl S, Garcia-Manero G, Cortes J. The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 113(6):1338-43, 7/2008. PMID: 18629842.
166. Verstovsek S, Tefferi A, Cortes J, O'Brien S, Garcia-Manero G, Pardanani A, Akin C, Faderl S, Manshouri T, Thomas D, Kantarjian H. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 14(12):3906-15, 6/15/2008. PMID: 18559612.
167. Garcia-Manero G, Stoltz ML, Ward MR, Kantarjian H, Sharma S. A pilot pharmacokinetic study of oral azacitidine. Leukemia 22(9):1680-4, 6/2008. e-Pub 6/2008. PMID: 18548103.
168. Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HM. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 112(5). e-Pub 6/2008. PMID: 18565853.
169. Quintás-Cardama A, Tong W, Manshouri T, Vega F, Lennon PA, Cools J, Gilliland DG, Lee F, Cortes J, Kantarjian H, Garcia-Manero G. Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies. Leukemia 22(6):1117-24, 6/2008. e-Pub 4/10/2008. PMID: 18401417.
170. Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer 112(11):2341-51, 6/2008. PMID: 18398832.
171. Kuang SQ, Tong WG, Yang H, Lin W, Lee MK, Fang ZH, Wei Y, Jelinek J, Issa JP, Garcia-Manero G. Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. Leukemia 22(8):1529-38, 6/2008. e-Pub 6/2008. PMID: 18528427.
172. Fabbri M, Garzon R, Andreeff M, Kantarjian HM, Garcia-Manero G, Calin GA. MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. Leukemia 22(6):1095-105, 6/2008. e-Pub 3/6/2008. PMID: 18323801.
173. Quintás-Cardama A, Tong W, Kantarjian H, Thomas D, Ravandi F, Kornblau S, Manshouri T, Cortes JE, Garcia-Manero G, Verstovsek S. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia 22(5):965-70, 5/2008. e-Pub 4/3/2008. PMID: 18385750.
174. Yanada M, Garcia-Manero G, Borthakur G, Ravandi F, Kantarjian H, Estey E. Relapse and death during first remission in acute myeloid leukemia. Haematologica 93(4):633-4, 4/2008. PMID: 18379012.
175. Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G, Wierda WG, Pierce S, Estey E, Liu J, Huang X, Kantarjian H. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 22(3):538-43, 3/2008. e-Pub 12/13/2007. PMID: 18079733.
176. Kantarjian H, O'Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S, Ravandi-Kashani F, Verstovsek S, Beth Rios M, Cortes J. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer 112(4):837-45, 2/15/2008. PMID: 18085610.
177. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, Ricker JL, Secrist JP, Richon VM, Frankel SR, Kantarjian HM. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111(3):1060-6, 2/1/2008. e-Pub 10/25/2007. PMID: 17962510.
178. Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 26(2):196-203, 1/10/2008. PMID: 18182662.
179. Jain N, Hubbard J, Vega F, Vidal G, Garcia-Manero G, Borthakur G. Spontaneous Remission of Acute Myeloid Leukemia: Report of Three Cases and Review of the Literature. Clinical Leukemia 2(1):64-67, 2008.
180. Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O'Brien S, Garcia-Manero G, Giles F, Breeden M, Reeves N, Wierda WG, Jones D. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 110(12):4005-11, 12/1/2007. e-Pub 9/4/2007. PMID: 17785585.
181. Yanada M, Garcia-Manero G, Borthakur G, Ravandi F, Kantarjian H, Estey E. Potential cure of acute myeloid leukemia : analysis of 1069 consecutive patients in first complete remission. Cancer 110(12):2756-60, 12/15/2007. PMID: 17948909.
182. Jabbour E, Kantarjian H, Cortes J, Thomas D, Garcia-Manero G, Ferrajoli A, Faderl S, Richie MA, Beran M, Giles F, Verstovsek S. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer 110(9):2012-8, 11/1/2007. PMID: 17849460.
183. Cortes J, Quintás-Cardama A, Garcia-Manero G, O'Brien S, Jones D, Faderl S, Ebarb T, Giles F, Thomas D, Kantarjian H. Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure. Cancer 110(9):2000-6, 11/1/2007. PMID: 17849425.
184. Jabbour E, Kantarjian HM, Abruzzo LV, O'Brien S, Garcia-Manero G, Verstovsek S, Shan J, Rios MB, Cortes J. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 110(8):2991-5, 10/15/2007. e-Pub 7/11/2007. PMID: 17625066.
185. Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda WG, Ouzounian S, Quezada A, Pierce S, Estey EH, Issa JP, Kantarjian HM, Garcia-Manero G. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110(7):2302-8, 10/2007. e-Pub 6/2007. PMID: 17596541.
186. Amin HM, Hoshino K, Yang H, Lin Q, Lai R, Garcia-Manero G. Decreased expression level of SH2 domain-containing protein tyrosine phosphatase-1 (Shp1) is associated with progression of chronic myeloid leukaemia. J Pathol 212(4):402-10, 8/2007. PMID: 17503411.
187. Yanada M, Huang X, Garcia-Manero G, O'brien S, Ravandi F, Borthakur G, Faderl S, Issa JP, Kantarjian H, Estey E. Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome. Br J Haematol 138(4):555-7, 8/2007. e-Pub 6/2007. PMID: 17593249.
188. Aribi A, Bueso-Ramos C, Estey E, Estrov Z, O'Brien S, Giles F, Faderl S, Thomas D, Kebriaei P, Garcia-Manero G, Pierce S, Cortes J, Kantarjian H, Ravandi F. Biphenotypic acute leukaemia: a case series. Br J Haematol 138(2):213-6, 7/2007. PMID: 17593028.
189. Qin T, Youssef EM, Jelinek J, Chen R, Yang AS, Garcia-Manero G, Issa JP. Effect of cytarabine and decitabine in combination in human leukemic cell lines. Clin Cancer Res 13(14):4225-32, 7/2007. PMID: 17634552.
190. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Cortes J, Thomas D, Garcia-Manero G, Koller C, Beran M, Giles F, Ravandi F, Lerner S, Kantarjian H, Keating M. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 109(11):4679-85, 6/2007. e-Pub 2/2007. PMID: 17299097.
191. Hoshino K, Quintás-Cardama A, Yang H, Sanchez-Gonzalez B, Garcia-Manero G. Aberrant DNA methylation of the Src kinase Hck, but not of Lyn, in Philadelphia chromosome negative acute lymphocytic leukemia. Leukemia 21(5):906-11, 5/2007. e-Pub 3/2007. PMID: 17344919.
192. Jabbour E, O'Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, Cabanillas M, Thomas DA. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 109(8):3214-8, 4/2007. e-Pub 1/2007. PMID: 17209054.
193. Kuang SQ, Ling X, Sanchez-Gonzalez B, Yang H, Andreeff M, Garcia-Manero G. Differential tumor suppressor properties and transforming growth factor-beta responsiveness of p57KIP2 in leukemia cells with aberrant p57KIP2 promoter DNA methylation. Oncogene 26(10):1439-48, 3/2007. e-Pub 8/2006. PMID: 16936778.
194. Oki Y, Kantarjian HM, Gharibyan V, Jones D, O'Brien S, Verstovsek S, Cortes J, Morris GM, Garcia-Manero G, Issa JP. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer 109(5):899-906, 3/2007. PMID: 17236224.
195. Boumber YA, Kondo Y, Chen X, Shen L, Gharibyan V, Konishi K, Estey E, Kantarjian H, Garcia-Manero G, Issa JP. RIL, a LIM Gene on 5q31, Is Silenced by Methylation in Cancer and Sensitizes Cancer Cells to Apoptosis. Cancer Res 67(5):1997-2005, 3/2007. PMID: 17332327.
196. Quintás-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Giles F, Thomas D, Wierda W, Cortes J. A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. Leuk Lymphoma 48(2):283-9, 2/2007. PMID: 17325887.
197. Aribi A, Kantarjian HM, Estey EH, Koller CA, Thomas DA, Kornblau SM, Faderl SH, Laddie NM, Garcia-Manero G, Cortes JE. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer 109(7):1355-9, 2/2007. PMID: 17326049.
198. Kantarjian HM, O'Brien S, Huang X, Garcia-Manero G, Ravandi F, Cortes J, Shan J, Davisson J, Bueso-Ramos CE, Issa JP. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 109(6):1133-7, 2/2007. PMID: 17315156.
199. Han X, Garcia-Manero G, McDonnell TJ, Lozano G, Medeiros LJ, Xiao L, Rosner G, Nguyen M, Fernandez M, Valentin-Vega YA, Barboza J, Jones DM, Rassidakis GZ, Kantarjian HM, Bueso-Ramos CE. HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. Mod Pathol 20(1):54-62, 1/2007. e-Pub 11/2006. PMID: 17143258.
200. Quintás-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Estrov Z, Giles F, Murgo A, Ladie N, Verstovsek S, Cortes J. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 109(2):248-55, 1/2007. PMID: 17154172.
201. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109(1):52-7, 1/2007. e-Pub 8/2006. PMID: 16882708.
202. Atallah E, Kantarjian H, Garcia-Manero G. The role of decitabine in the treatment of myelodysplastic syndromes. Expert Opin Pharmacother 8(1):65-73, 1/2007. PMID: 17163808.
203. Kantarjian HM, O'Brien S, Shan J, Aribi A, Garcia-Manero G, Jabbour E, Ravandi F, Cortes J, Davisson J, Issa JP. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 109(2):265-73, 1/2007. PMID: 17133405.
204. Garcia-Manero G. Modifying the epigenome as a therapeutic strategy in myelodysplasia. Hematology Am Soc Hematol Educ Program 2007:405-11, 2007. PMID: 18024658.
205. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'Brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa JP. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 108(10):3271-9, 11/2006. PMCID: PMC1895437.
206. Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S, Zhou X, Luthra R, Garcia-Manero G, Giles F, Rios MB, Verstovsek S, Cortes J. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20(10):1767-73, 10/2006. PMID: 16855631.
207. Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV, Cortes J. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood 108(8):2811-3, 10/2006. PMID: 16809614.
208. Kantarjian HM, Talpaz M, O'Brien S, Jones D, Giles F, Garcia-Manero G, Faderl S, Ravandi F, Rios MB, Shan J, Cortes J. Survival Benefit with Imatinib Mesylate versus Interferon Alpha-Based Regimens in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia. Blood 108(6):1835-40, 9/2006. PMID: 16709931.
209. Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, Masson E, Rae P, Laird G, Sharma S, Kantarjian H, Dugan M, Albitar M, Bhalla K. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 12(15):4628-35, 8/2006. PMID: 16899611.
210. Sanchez-Gonzalez B, Yang H, Bueso-Ramos C, Hoshino K, Quintas-Cardama A, Richon VM, Garcia-Manero G. Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood 108(4):1174-82, 8/2006. PMCID: PMC1895868.
211. Tsimberidou AM, Estey E, Kantarjian H, Keating MJ, Pierce S, Garcia-Manero G. Granulocyte colony stimulating factor administration associated with cerebral hemorrhage in acute promyelocytic leukemia. Leukemia 20(8):1452-3, 8/2006. PMID: 16728980.
212. Tsimberidou AM, Catovsky D, Schlette E, O'Brien S, Wierda WG, Kantarjian H, Garcia-Manero G, Wen S, Do KA, Lerner S, Keating MJ. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer 107(1):125-35, 7/2006. PMID: 16700034.
213. Yee KW, Cortes J, Ferrajoli A, Garcia-Manero G, Verstovsek S, Wierda W, Thomas D, Faderl S, King I, O'brien SM, Jeha S, Andreeff M, Cahill A, Sznol M, Giles FJ. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Leuk Res 30(7):813-22, 7/2006. PMID: 16478631.
214. Giles F, Verstovsek S, Garcia-Manero G, Thomas D, Ravandi F, Wierda W, Ferrajoli A, Kornblau S, Jabbour E, Shan J, O'brien S, Albitar M, Kantarjian H. Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. Br J Haematol 134(1):58-60, 7/2006. PMID: 16803568.
215. Tibes R, Keating MJ, Ferrajoli A, Wierda W, Ravandi F, Garcia-Manero G, O'Brien S, Cortes J, Verstovsek S, Browning ML, Faderl S. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer 106(12):2645-51, 6/2006. PMID: 16688777.
216. Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK, Gharybian V, Luna R, Rashid A, Shen L, Estecio MR, Kantarjian HM, Garcia-Manero G, Issa JP. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. Cancer Res 66(10):5495-503, 5/2006. PMID: 16707479.
217. Thomas DA, Giles FJ, Albitar M, Cortes JE, Verstovsek S, Faderl S, O'Brien SM, Garcia-Manero G, Keating MJ, Pierce S, Zeldis J, Kantarjian HM. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer 106(9):1974-84, 5/2006. PMID: 16583431.
218. Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, Kantarjian H. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 107(9):3469-73, 5/2006. PMID: 16373661.
219. Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106(7):1569-80, 4/2006. PMID: 16502413.
220. Soper SA, Brown K, Ellington A, Frazier B, Garcia-Manero G, Gau V, Gutman SI, Hayes DF, Korte B, Landers JL, Larson D, Ligler F, Majumdar A, Mascini M, Nolte D, Rosenzweig Z, Wang J, Wilson D. Point-of-care biosensor systems for cancer diagnostics/prognostics. Biosens Bioelectron 21(10):1932-42, 4/2006. PMID: 16473506.
221. Patel SP, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Kantarjian H, Estey E. Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia. Leuk Res 30(3):362-3, 3/2006. PMID: 16168477.
222. Kantarjian H, O'Brien S, Cortes J, Giles F, Faderl S, Jabbour E, Garcia-Manero G, Wierda W, Pierce S, Shan J, Estey E. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 106(5):1090-8, 3/2006. PMID: 16435386.
223. Cortes JE, Talpaz M, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Rios MB, Shan J, Kantarjian HM. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer 106(6):1306-15, 3/2006. PMID: 16463391.
224. Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E, Garcia-Manero G. Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood 107(3):880-4, 2/2006. PMID: 16123215.
225. Wierda W, O'Brien S, Faderl S, Ferrajoli A, Wang X, Do KA, Garcia-Manero G, Thomas D, Cortes J, Ravandi-Kashani F, Giles F, Lerner S, Kantarjian H, Keating M. A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer 106(2):337-45, 1/2006. PMID: 16353201.
226. Faderl S, Verstovsek S, Cortes J, Ravandi F, Beran M, Garcia-Manero G, Ferrajoli A, Estrov Z, O'Brien S, Koller C, Giles FJ, Wierda W, Kwari M, Kantarjian HM. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients >= 50 years. Blood 108(1):45-51, 1/2006. PMID: 16403905.
227. Borthakur G, Kantarjian H, Daley G, Talpaz M, O'Brien S, Garcia-Manero G, Giles F, Faderl S, Sugrue M, Cortes J. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer 106(2):346-52, 1/2006. PMID: 16342165.
228. Jabbour E, Kantarjian H, O'Brien S, Rios MB, Abruzzo L, Verstovsek S, Garcia-Manero G, Cortes J. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood 107(2):480-2, 1/2006. PMID: 16195326.
229. Thomas DA, Sarris AH, Cortes J, Faderl S, O'Brien S, Giles FJ, Garcia-Manero G, Rodriguez MA, Cabanillas F, Kantarjian H. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer 106(1):120-7, 2006. PMID: 16331634.
230. Giles F, Verstovsek S, Thomas D, Gerson S, Cortes J, Faderl S, Ferrajoli A, Ravandi F, Kornblau S, Garcia-Manero G, Jabbour E, O'Brien S, Karsten V, Cahill A, Yee K, Albitar M, Sznol M, Kantarjian H. Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. Clin Cancer Res 11(21):7817-24, 11/2005. PMID: 16278404.
231. Ravandi F, O'Brien S, Jones D, Lerner S, Faderl S, Ferrajoli A, Wierda W, Garcia-Manero G, Thomas D, Koller C, Verstovsek S, Giles F, Cortes J, Herling M, Kantarjian H, Keating M. T-cell prolymphocytic leukemia: a single-institution experience. Clin Lymphoma Myeloma 6(3):234-9, 11/2005. PMID: 16354329.
232. Yee KW, Hagey A, Verstovsek S, Cortes J, Garcia-Manero G, O'Brien SM, Faderl S, Thomas D, Wierda W, Kornblau S, Ferrajoli A, Albitar M, McKeegan E, Grimm DR, Mueller T, Holley-Shanks RR, Sahelijo L, Gordon GB, Kantarjian HM, Giles FJ. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 11(18):6615-24, 9/2005. PMID: 16166440.
233. Jabbour E, Verstovsek S, Giles F, Gandhi V, Cortes J, O'Brien S, Plunkett W, Garcia-Manero G, Jackson CE, Kantarjian H, Andreeff M. 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer 104(3):541-6, 8/2005. PMID: 15977212.
234. Canalli AA, Yang H, Jeha S, Hoshino K, Sanchez-Gonzalez B, Brandt M, Pierce S, Kantarjian H, Issa JP, Garcia-Manero G. Aberrant DNA methylation of a cell cycle regulatory pathway composed of P73, P15 and P57KIP2 is a rare event in children with acute lymphocytic leukemia. Leuk Res 29(8):881-5, 8/2005. PMID: 15978938.
235. Giles F, O'Brien S, Cortes J, Verstovsek S, Bueso-Ramos C, Shan J, Pierce S, Garcia-Manero G, Keating M, Kantarjian H. Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer 104(3):547-54, 8/2005. PMID: 15973664.
236. Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H, Garcia-Manero G. Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid. Leuk Res 29(7):739-48, 7/2005. PMID: 15927669.
237. Giles FJ, Kantarjian HM, Cortes JE, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Mattiuzzi GN, Tsimberidou AM, Albitar M, O'Brien SM, Estey E. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Leuk Res 29(6):649-52, 6/2005. PMID: 15863204.
238. Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H, Keating M. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23(18):4070-8, 6/2005. PMID: 15767647.
239. Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, Talpaz M, Garcia-Manero G, Kantarjian HM. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 23(17):3948-56, 6/2005. PMID: 15883410.
240. Bueso-Ramos C, Xu Y, McDonnell TJ, Brisbay S, Pierce S, Kantarjian H, Rosner G, Garcia-Manero G. Protein expression of a triad of frequently methylated genes, p73, p57Kip2, and p15, has prognostic value in adult acute lymphocytic leukemia independently of its methylation status. J Clin Oncol 23(17):3932-9, 6/2005. PMID: 15851765.
241. Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Rios MB, Kantarjian H. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 11(9):3425-32, 5/2005. PMID: 15867244.
242. Kantarjian H, Talpaz M, O'Brien S, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Shan J, Rios MB, Champlin R, de Lima M, Cortes J. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience. Cancer 103(10):2099-108, 5/2005. PMID: 15830345.
243. Cortes J, Faderl S, Estey E, Kurzrock R, Thomas D, Beran M, Garcia-Manero G, Ferrajoli A, Giles F, Koller C, O'Brien S, Wright J, Bai SA, Kantarjian H. Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. J Clin Oncol 23(12):2805-12, 4/2005. PMID: 15728224.
244. Murai M, Toyota M, Satoh A, Suzuki H, Akino K, Mita H, Sasaki Y, Ishida T, Shen L, Garcia-Manero G, Issa JP, Hinoda Y, Tokino T, Imai K. Aberrant DNA methylation associated with silencing BNIP3 gene expression in haematopoietic tumours. Br J Cancer 92(6):1165-72, 3/2005. PMCID: PMC2361956.
245. Quintas-Cardama A, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Rios MB, Hayes K, Glassman A, Bekele BN, Zhou X, Cortes J. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 105(6):2281-6, 3/2005. PMID: 15572595.
246. Faderl S, Gandhi V, O'Brien S, Bonate P, Cortes J, Estey E, Beran M, Wierda W, Garcia-Manero G, Ferrajoli A, Estrov Z, Giles FJ, Du M, Kwari M, Keating M, Plunkett W, Kantarjian H. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 105(3):940-7, 2/2005. PMID: 15486072.
247. Saba R, Jabbour E, Giles F, Cortes J, Talpaz M, O’Brien S, Freireich EJ, Garcia-Manero G, Kantarjian H, Verstovsek S. Interferon-alpha (IFN-a) Therapy for Patients with Essential Thrombocythemia (ET): Final Results of a Phase II Study Initiated in 1986. Cancer 103(12):2551-2557, 2005.
248. Grosso D, Filicko J, Garcia-Manero G, Beardell F, Brunner J, Cohn J, Ferbér A, Martinez J, Mookerjee B, Rose L, Tice D, Wagner JL, Capizzi R, Flomenberg N. Cytoprotection in acute myelogenous leukemia (AML) therapy. Semin Oncol 31(6 Suppl 18):67-73, 12/2004. PMID: 15726527.
249. Hennessy B, Giles F, Cortes J, O'brien S, Ferrajoli A, Ossa G, Garcia-Manero G, Faderl S, Kantarjian H, Verstovsek S. Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience. Am J Hematol 77(3):209-14, 11/2004. PMID: 15495258.
250. Kantarjian HM, Cortes JE, O'Brien S, Luthra R, Giles F, Verstovsek S, Faderl S, Thomas D, Garcia-Manero G, Rios MB, Shan J, Jones D, Talpaz M. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood 104(7):1979-88, 10/2004. PMID: 15198956.
251. Tsimberidou AM, Estey E, Whitman GJ, Dryden MJ, Ratnam S, Pierce S, Faderl S, Giles F, Kantarjian HM, Garcia-Manero G. Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. Leuk Res 28(9):991-4, 9/2004. PMID: 15234578.
252. Tsimberidou AM, Medina J, Cortes J, Rios A, Bonnie G, Faderl S, Kantarjian H, Garcia-Manero G. Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature. Leuk Res 28(6):657-60, 6/2004. PMID: 15120945.
253. Quintas-Cardama A, Kantarjian H, O'Brien S, Garcia-Manero G, Rios MB, Talpaz M, Cortes J. Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer 100(12):2592-7, 6/2004. PMID: 15197801.
254. Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, Garcia-Manero G, Keating MJ, Andreeff M, Jeha S, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Talpaz M, Kantarjian H. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103(12):4396-407, 6/2004. PMID: 14551133.
255. Giles F, Thomas D, Garcia-Manero G, Faderl S, Cortes J, Verstovsek S, Ferrajoli A, Jeha S, Beran M, Koller C, Andreeff M, Cahill A, Clairmont C, Sznol M, Kantarjian H. A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia. Clin Cancer Res 10(9):2908-17, 5/2004. PMID: 15131024.
256. Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S, Garcia-Manero G, McConkey D, Ruiz SL, Patel G, Guerciolini R, Wright J, Kantarjian H. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 10(10):3371-6, 5/2004. PMID: 15161691.
257. Tsao AS, Kantarjian H, Thomas D, Giles F, Cortes J, Garcia-Manero G, Huh Y, Yang Y, Shen Y, Albitar M, Estey E. C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome. Leuk Res 28(4):373-8, 4/2004. PMID: 15109537.
258. Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, Rios MB, Shan J, Letvak L, Thomas D, Faderl S, Ferrajoli A, Cortes J. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103(8):2873-8, 4/2004. PMID: 15070658.
259. Youssef EM, Chen XQ, Higuchi E, Kondo Y, Garcia-Manero G, Lotan R, Issa JP. Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers. Cancer Res 64(7):2411-7, 4/2004. PMID: 15059893.
260. Giles FJ, Tallman MS, Garcia-Manero G, Cortes JE, Thomas DA, Wierda WG, Verstovsek S, Hamilton M, Barrett E, Albitar M, Kantarjian HM. Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia. Cancer 100(7):1449-58, 4/2004. PMID: 15042679.
261. Kurzrock R, Albitar M, Cortes JE, Estey EH, Faderl SH, Garcia-Manero G, Thomas DA, Giles FJ, Ryback ME, Thibault A, De Porre P, Kantarjian HM. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol 22(7):1287-92, 4/2004. PMID: 15051776.
262. El-Zimaity MM, Kantarjian H, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Verstovsek S, Thomas D, Ferrajoli A, Hayes K, Nebiyou Bekele B, Zhou X, Rios MB, Glassman AB, Cortes JE. Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol 125(2):187-95, 4/2004. PMID: 15059141.
263. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103(5):1635-40, 3/2004. PMID: 14604977.
264. Mattiuzzi GN, Kantarjian H, Faderl S, Lim J, Kontoyiannis D, Thomas D, Wierda W, Raad I, Garcia-Manero G, Zhou X, Ferrajoli A, Bekele N, Estey E. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer 100(3):581-9, 2/2004. PMID: 14745876.
265. Zangari M, Anaissie E, Stopeck A, Morimoto A, Tan N, Lancet J, Cooper M, Hannah A, Garcia-Manero G, Faderl S, Kantarjian H, Cherrington J, Albitar M, Giles FJ. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res 10(1 Pt 1):88-95, 2004. PMID: 14734456.
266. Kantarjian H, O'Brien S, Cortes J, Giles F, Shan J, Rios MB, Faderl S, Verstovsek S, Garcia-Manero G, Wierda W, Kornblau S, Ferrajoli A, Keating M, Talpaz M. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. Clin Cancer Res 10(1 Pt 1):68-75, 2004. PMID: 14734453.
267. Hennessy BT, Garcia-Manero G, Kantarjian HM, Giles FJ. DNA methylation in haematological malignancies: the role of decitabine. Expert Opin Investig Drugs 12(12):1985-93, 12/2003. PMID: 14640942.
268. Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Rios MB, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Keating M, Talpaz M. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer 98(12):2636-42, 12/2003. PMID: 14669283.
269. Tsimberidou AM, Estey E, Cortes JE, Garcia-Manero G, Faderl S, Verstovsek S, Thomas DA, Ferrajoli A, Keating MJ, O'Brien S, Kantarjian HM, Giles FJ. Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol 52(6):449-52, 12/2003. PMID: 13680159.
270. Giles FJ, Fracasso PM, Kantarjian HM, Cortes JE, Brown RA, Verstovsek S, Alvarado Y, Thomas DA, Faderl S, Garcia-Manero G, Wright LP, Samson T, Cahill A, Lambert P, Plunkett W, Sznol M, DiPersio JF, Gandhi V. Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res 27(12):1077-83, 12/2003. PMID: 12921943.
271. Medina J, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Giles F, Rios MB, Hayes K, Cortes J. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 98(9):1905-11, 11/2003. PMID: 14584073.
272. Yang AS, Estecio MR, Garcia-Manero G, Kantarjian HM, Issa JP. Comment on "Chromosomal instability and tumors promoted by DNA hypomethylation" and "Induction of tumors in nice by genomic hypomethylation". Science 302(5648):1153; author reply 1153, 11/2003. PMID: 14615517.
273. Kantarjian H, O'Brien S, Cortes J, Shan J, Giles F, Garcia-Manero G, Verstovsek S, Faderl S, Rios MB, Talpaz M. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase. Cancer 98(7):1430-7, 10/2003. PMID: 14508830.
274. Tsimberidou A, Cortes J, Thomas D, Garcia-Manero G, Verstovsek S, Faderl S, Albitar M, Kantarjian H, Estey E, Giles FJ. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res 27(10):893-7, 10/2003. PMID: 12860008.
275. Kantarjian H, Gandhi V, Cortes J, Verstovsek S, Du M, Garcia-Manero G, Giles F, Faderl S, O'Brien S, Jeha S, Davis J, Shaked Z, Craig A, Keating M, Plunkett W, Freireich EJ. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 102(7):2379-86, 10/2003. PMID: 12791647.
276. Cortes J, Talpaz M, O'Brien S, Giles F, Beth Rios M, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Kantarjian H. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 98(6):1105-13, 9/2003. PMID: 12973833.
277. O'Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S, Garcia-Manero G, White K, Mallard S, Freireich E, Kantarjian HM. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer 98(5):888-93, 9/2003. PMID: 12942553.
278. Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Faderl S, Issa JP, Garcia-Manero G, Rios MB, Shan J, Andreeff M, Keating M, Talpaz M. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 98(3):522-8, 8/2003. PMID: 12879469.
279. Cortes J, Giles F, O'Brien S, Thomas D, Garcia-Manero G, Rios MB, Faderl S, Verstovsek S, Ferrajoli A, Freireich EJ, Talpaz M, Kantarjian H. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood 102(1):83-6, 7/2003. PMID: 12637317.
280. Estey E, Giles F, Cortes J, Beran M, Verstovsek S, Garcia-Manero G, Faderl S, Kantarjian H. Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML. Leuk Res 27(6):475-9, 6/2003. PMID: 12648505.
281. Tsimberidou AM, Kantarjian HM, Estey E, Cortes JE, Verstovsek S, Faderl S, Thomas DA, Garcia-Manero G, Ferrajoli A, Manning JT, Keating MJ, Albitar M, O'Brien S, Giles FJ. Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia 17(6):1100-3, 6/2003. PMID: 12764375.
282. Cortes J, Giles F, O'Brien S, Thomas D, Albitar M, Rios MB, Talpaz M, Garcia-Manero G, Faderl S, Letvak L, Salvado A, Kantarjian H. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer 97(11):2760-6, 6/2003. PMID: 12767088.
283. Garcia-Manero G, Talpaz M, Giles FJ, Cortes J, Faderl S, O'Brien S, Thomas D, Verstovsek S, Beth Rios M, Shan J, Ferrajoli A, Wierda W, Kantarjian HM. Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside. Cancer 97(12):3010-6, 6/2003. PMID: 12784336.
284. Shen L, Toyota M, Kondo Y, Obata T, Daniel S, Pierce S, Imai K, Kantarjian HM, Issa JP, Garcia-Manero G. Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood 101(10):4131-6, 5/2003. PMID: 12586619.
285. Giles FJ, Kantarjian HM, Cortes JE, Garcia-Manero G, Verstovsek S, Faderl S, Thomas DA, Ferrajoli A, O'Brien S, Wathen JK, Xiao LC, Berry DA, Estey EH. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol 21(9):1722-7, 5/2003. PMID: 12721247.
286. Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, Andreeff M, Beran M, Cortes J, Wierda W, Tran N, Keating MJ. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101(9):3413-5, 5/2003. PMID: 12522009.
287. Kantarjian H, Talpaz M, O'Brien S, Giles F, Rios MB, White K, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Kornblau S, Cortes J. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 97(9):2225-8, 5/2003. PMID: 12712475.
288. Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J, Garcia-Manero G, Faderl S, Thomas DA, Wierda W, Ferrajoli A, Jeha S, Kantarjian HM. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 101(10):3794-800, 5/2003. PMID: 12560227.
289. Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, Verstovsek S, Ferrajoli A, Wierda W, Alvarado Y, O'Brien SM, Albitar M, Keating MJ, Giles FJ. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer 97(7):1711-20, 4/2003. PMID: 12655528.
290. Apostolidou E, Estey E, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Tsimberidou A, Kantarjian H, Giles FJ. Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia. Leuk Res 27(4):301-4, 4/2003. PMID: 12531220.
291. Giles FJ, Cooper MA, Silverman L, Karp JE, Lancet JE, Zangari M, Shami PJ, Khan KD, Hannah AL, Cherrington JM, Thomas DA, Garcia-Manero G, Albitar M, Kantarjian HM, Stopeck AT. Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases. Cancer 97(8):1920-8, 4/2003. PMID: 12673719.
292. Cortes J, Kantarjian H, Albitar M, Thomas D, Faderl S, Koller C, Garcia-Manero G, Giles F, Andreeff M, O'Brien S, Keating M, Estey E. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cancer 97(5):1234-41, 3/2003. PMID: 12599230.
293. Cortes J, Albitar M, Thomas D, Giles F, Kurzrock R, Thibault A, Rackoff W, Koller C, O'Brien S, Garcia-Manero G, Talpaz M, Kantarjian H. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 101(5):1692-7, 3/2003. PMID: 12411300.
294. Tsimberidou A, Estey E, Cortes J, Thomas D, Faderl S, Verstovsek S, Garcia-Manero G, Keating M, Albitar M, O'Brien S, Kantarjian H, Giles F. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer 97(6):1481-7, 3/2003. PMID: 12627513.
295. Tsimberidou AM, Medina J, Earl M, Sierra M, Shriki JE, Bueso-Ramos C, Giralt S, Beran M, Giles FJ, Garcia-Manero G. Metastatic gastric adenocarcinoma following allogeneic stem cell transplantation in a patient with acute myelogenous leukemia. Bone Marrow Transplant 31(5):413-4, 3/2003. PMID: 12634736.
296. Giles FJ, Faderl S, Thomas DA, Cortes JE, Garcia-Manero G, Douer D, Levine AM, Koller CA, Jeha SS, O'Brien SM, Estey EH, Kantarjian HM. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. J Clin Oncol 21(6):1050-6, 3/2003. PMID: 12637470.
297. Garcia-Manero G, Jeha S, Daniel J, Williamson J, Albitar M, Kantarjian HM, Issa JP. Aberrant DNA methylation in pediatric patients with acute lymphocytic leukemia. Cancer 97(3):695-702, 2/2003. PMID: 12548613.
298. Kantarjian HM, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Faderl S, Thomas D, Shan J, Rios MB, Cortes J. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 101(2):473-5, 1/2003. PMID: 12393385.
299. Kantarjian HM, Cortes JE, O'Brien S, Giles F, Garcia-Manero G, Faderl S, Thomas D, Jeha S, Rios MB, Letvak L, Bochinski K, Arlinghaus R, Talpaz M. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 101(1):97-100, 2003. PMID: 12393600.
300. Alvarado Y, Tsimberidou A, Kantarjian H, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Estey E, Giles FJ. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol 51(1):87-90, 2003. PMID: 12497211.
301. Shen L, Kondo Y, Issa JP, Garcia-Manero G. Lack of p21(CIP1) DNA methylation in acute lymphocytic leukemia. Blood 100(9):3432-3; author reply 3433-4, 11/2002. PMID: 12412576.
302. Giles F, Garcia-Manero G, Cortes J, Thomas D, Kantarjian H, Estey E. Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy. Haematologica 87(10):1114-6, 10/2002. PMID: 12368170.
303. Kantarjian HM, O'Brien S, Cortes JE, Giralt SA, Rios MB, Shan J, Giles FJ, Thomas DA, Faderl S, De Lima M, Garcia-Manero G, Champlin R, Arlinghaus R, Talpaz M. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 100(5):1590-5, 9/2002. PMID: 12176876.
304. Garcia-Manero G, Kantarjian HM, Kornblau S, Estey E. Therapy-related myelodysplastic syndrome or acute myelogenous leukemia in patients with acute promyelocytic leukemia (APL). Leukemia 16(9):1888, 9/2002. PMID: 12200720.
305. Garcia-Manero G, Faderl S, Giles F, Thomas D, Cortes J, O'Brien S, Davis J, Kantarjian HM, Estey E. A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes. Haematologica 87(8):804-7, 8/2002. PMID: 12161355.
306. Garcia-Manero G, Daniel J, Smith TL, Kornblau SM, Lee MS, Kantarjian HM, Issa JP. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res 8(7):2217-24, 7/2002. PMID: 12114423.
307. Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S, Thomas DA, Garcia-Manero G, Issa JP, Andreeff M, Kornblau SM, Koller C, Beran M, Keating M, Rios MB, Shan J, Resta D, Capdeville R, Hayes K, Albitar M, Freireich EJ, Cortes JE. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res 8(7):2177-87, 7/2002. PMID: 12114418.
308. Giles FJ, Cortes JE, Thomas DA, Garcia-Manero G, Faderl S, Jeha S, De Jager RL, Kantarjian HM. Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia. Clin Cancer Res 8(7):2134-41, 7/2002. PMID: 12114413.
309. Kantarjian HM, O'Brien S, Cortes JE, Smith TL, Rios MB, Shan J, Yang Y, Giles FJ, Thomas DA, Faderl S, Garcia-Manero G, Jeha S, Wierda W, Issa JP, Kornblau SM, Keating M, Resta D, Capdeville R, Talpaz M. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res 8(7):2167-76, 7/2002. PMID: 12114417.
310. Garcia-Manero G, Bueso-Ramos C, Daniel J, Williamson J, Kantarjian HM, Issa JP. DNA methylation patterns at relapse in adult acute lymphocytic leukemia. Clin Cancer Res 8(6):1897-903, 6/2002. PMID: 12060634.
311. Faderl S, Keating MJ, Do KA, Liang SY, Kantarjian HM, O'Brien S, Garcia-Manero G, Manshouri T, Albitar M. Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia 16(6):1045-52, 6/2002. PMID: 12040436.
312. Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, Shan J, Faderl S, Garcia-Manero G, Thomas DA, Resta D, Talpaz M. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 99(10):3547-53, 5/2002. PMID: 11986206.
313. Verstovsek S, Lin H, Kantarjian H, Saglio G, De Micheli D, Pane F, Garcia-Manero G, Intrieri M, Rotoli B, Salvatore F, Guo JQ, Talpaz M, Specchia G, Pizzolo G, Liberati AM, Cortes J, Quackenbush RC, Arlinghaus RB. Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course. Cancer 94(9):2416-25, 5/2002. PMID: 12015767.
314. O'Brien S, Talpaz M, Cortes J, Shan J, Giles FJ, Faderl S, Thomas D, Garcia-Manero G, Mallard S, Beth M, Koller C, Kornblau S, Andreeff M, Murgo A, Keating M, Kantarjian HM. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer 94(7):2024-32, 4/2002. PMID: 11932905.
315. Giles FJ, Garcia-Manero G, Cortes JE, Baker SD, Miller CB, O'Brien SM, Thomas DA, Andreeff M, Bivins C, Jolivet J, Kantarjian HM. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. J Clin Oncol 20(3):656-64, 2/2002. PMID: 11821445.
316. Giles F, Garcia-Manero G, O'Brien S, Estey E, Kantarjian H. Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome. Acta Haematol 108(3):164-7, 2002. PMID: 12373091.
317. Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, Estey EH. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 92(2):406-13, 7/2001. PMID: 11466696.
318. Giles F, Cortes J, Garcia-Manero G, Kornblau S, Estey E, Kwari M, Murgo A, Kantarjian H. Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia. Invest New Drugs 19(1):13-20, 2001. PMID: 11291829.
319. García-Manero G, Schuster SJ, Patrick H, Martinez J. Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases. Am J Hematol 60(2):130-5, 2/1999. PMID: 9929105.
320. Chowdhury ZA, Barsigian C, Chalupowicz GD, Bach TL, Garcia-Manero G, Martinez J. Colocalization of tissue transglutaminase and stress fibers in human vascular smooth muscle cells and human umbilical vein endothelial cells. Exp Cell Res 231(1):38-49, 2/1997. PMID: 9056410.
321. García-Manero G, Dómine M. Daunomicine inhibits the catenation activity of the enzyme DNA topoisomerase II in an in vitro system. Oncología (Spain) 15:305-310, 1992.
322. García-Manero G. Chromosomal Fragile Sites and the enzyme DNA topoisomerase II. Graduation thesis, Faculty of Medicine, University of Zaragoza. Annals of the Faculty of Medicine of the University of Zaragoza, 11/1991.

Invited Articles

1. Garcia-Manero G. Improving survival in myelodysplastic syndromes. Lancet Oncol 10(3):223-232, 3/2009. PMID: 19261248.
2. Jain N, Rossi A, Garcia-Manero G. Epigenetic therapy of leukemia: An update. Int J Biochem Cell Biol 41(1):72-80, 1/2009. e-Pub 10/2008. PMID: 18948224.
3. Garcia-Manero G, Yang H, Kuang SQ, O'Brien S, Thomas D, Kantarjian H. Epigenetics of acute lymphocytic leukemia. Semin Hematol 46(1):24-32, 1/2009. PMID: 19100365.
4. Garcia-Manero G. All MDS Patients Are Not the Same. Clinical Advances in Hematology & Oncology 6(12):8-10, 12/2008.
5. Garcia-Manero G. Advances in MDS Management. Medical Progress 7(11):15-16, 11/2008.
6. Garcia-Manero G. Demethylating agents in myeloid malignancies. Curr Opin Oncol 20(6):705-10, 11/2008. PMID: 18841054.
7. Kim H, Garcia-Manero G. Management of Myelodysplastic Syndromes: Just the Beginning. Oncology 22(12):1360-1368, 11/2008.
8. Kantarjian H, O'Brien S, Cortes J, Wierda W, Faderl S, Garcia-Manero G, Issa JP, Estey E, Keating M, Freireich EJ. Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer 113(7 Suppl):1933-52, 10/2008. PMID: 18798533.
9. Atallah E, Garcia-Manero G. Treatment strategies in myelodysplastic syndromes. Cancer Invest 26(2):208-216, 3/2008. PMID: 18259954.
10. Garcia-Manero G, Yang AS, Jagasia M. Evaluating new treatment options for MDS. Clin Adv Hematol Oncol 5(11):1-9, 11/2007. PMID: 18185491.
11. Atallah E, Garcia-Manero G. Use of hypomethylating agents in myelodysplastic syndromes. Clin Adv Hematol Oncol 5(7):544-52, 7/2007. PMID: 17679928.
12. Garcia-Manero G. Recent Advances in the Treatment of MDS. A review of selected presentations from the 48th Annual Meeting of the American Society of Hematology, December 9-12, 2006, Orlando, Florida. Clin Adv Hematol Oncol 5(3 Suppl 6):1-13; quiz 15-6, 3/2007. PMID: 17519888.
13. Garcia-Manero G. Histone Deacetylases: Transcriptional regulation and other cellular functions. Br J Cancer 96(7):1153, 2007.
14. Garcia-Manero G. Recent advances in the treatment of MDS. Clinical Advances in Hematology & Oncology 3(6):1-16, 2007.
15. Garcia-Manero, G. Using combination therapy to improve control: DNA methylation and HDAC inhibition. The Promise of Epigenetic Therapy:14-18, 2007.
16. Garcia-Manero G, Saba HI. Decitabine in myelodysplastic syndromes: viewpoints. Drugs 66(7):959-60, 2006. PMID: 16740015.
17. Garcia-Manero G, Gore SD. Future directions for the use of hypomethylating agents. Semin Hematol 42(3 Suppl 2):S50-9, 7/2005. PMID: 16015506.
18. Garcia-Manero G, Issa JP. Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents. Cancer Invest 23(7):635-42, 2005. PMID: 16305991.
19. Garcia-Manero G, Glantz M. Leukemia and lymphoma: what is the role for intrathecal prophylactic treatment in adults? Expert Rev Neurother 4(4 Suppl):S25-31, 7/2004. PMID: 15853552.
20. Garcia-Manero G. Alteraciones epigeneticas en leucemias agudas. Haematologia 1:44, 2004.
21. Garcia-Manero G. Avances en leucemia linfocitica cronica. Haematolologia 1:34, 2004.
22. Garcia-Manero G. Front line therapy for patients with chronic myelogenous leukemia in chronic phase in the year 2004. Haematologica 89:57-61, 2004.
23. Garcia-Manero G. on DNA Hypomethylation in the Treatment of MDS. Clinical Advances in Hematology & Oncology 4(4):3, 2004.
24. Garcia-Manero G, Faderl S, O'Brien S, Cortes J, Talpaz M, Kantarjian HM. Chronic myelogenous leukemia: a review and update of therapeutic strategies. Cancer 98(3):437-57, 8/2003. PMID: 12879460.
25. Faderl S, Garcia-Manero G, Thomas DA, Kantarjian HM. Philadelphia chromosome-positive acute lymphoblastic leukemia- current concepts and future perspectives. Rev Clin Exp Hematol 6(2):142-60; discussion 200-2, 6/2002. PMID: 12196213.
26. Garcia-Manero G, Talpaz M, Kantarjian HM. Current therapy of chronic myelogenous leukemia. Intern Med 41(4):254-64, 4/2002. PMID: 11993784.
27. Garcia-Manero G Kantarjian H. Imatinib mesylate in accelerated-phase Philadelphia chromosome positive chronic myelogenous leukemia. American Journal Oncology Review 1:208-228, 2002.
28. Garcia-Manero G Kantarjian H. Treatment innovations in chronic myelogenous leukemia. Hematologia (Argentina) supl II:19-25, 2002.
29. Garcia-Manero G Kantarjian H. Treatment innovations in chronic myelogenous leukemia. Oncology Special 5:139-143.3, 2002.
30. Garcia-Manero G, Thomas DA. Salvage therapy for refractory or relapsed acute lymphocytic leukemia. Hematol Oncol Clin North Am 15(1):163-205, 2/2001. PMID: 11253606.
31. Garcia-Manero G, Keating MJ, O'Brien S. Fludarabine, cyclophosphamide, and rituximab in chronic lymphocytic leukemia. Biological Therapy of Lymphoma 4:7-9, 2001.
32. Garcia-Manero G, Kantarjian HM. The hyper-CVAD regimen in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am 14(6):1381-96, x-xi, 12/2000. PMID: 11147229.
33. Garcia-Manero G, Issa J-P. CpG island methylation in cancer. Cancer Research Alert 1:133-144, 2000.
34. Garcia-Manero G, Schuster SJ, Agha ME. Should autologous or allogeneic stem-cell therapy be a part of consolidation therapy for all cases of adult acute myelogenous leukemia? Semin Oncol 26(1):xvi-xvii, xxi-xxii, 2/1999. PMID: 10073556.
35. Sorensen SC, García-Manero G, Mastrangelo MJ, Soltan A. Does lymph node dissection still have a role in cancer therapy? Semin Oncol 24(3):xxxiii-xxxiv, xxxix, xli-xlii, xlv, 6/1997. PMID: 9208880.
36. Garcia-Manero G, Domine M, Delgado C, Cunningham JM, Francis GE. The polymerase chain reaction (PCR): a new technique for the molecular study of cancer. Oncologia 15:501-516, 1991.

Editorials

1. Garcia-Manero G. Prognostic implications of epigenetic silencing of p15INK4B in acute promyelocytic leukemia. Leukemia 17(5):839-40, 5/2003. PMID: 12750694.
2. Garcia-Manero, G. Methylation, aging and pediatric acute lymphocytic leukemia. Leukemia 17:2063-2064, 2003.

Book Chapters

1. Stevenson W, Garcia-Manero G. Epigenetics of leukemia. In: Childhood Leukemias, 3rd. Ed(s) Ching-Hon Pui. Cambridge University Press: United Kingdom, 239-236, 2012.
2. Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Foran JM, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Schroeder MA, Shami PJ, Stone RM, Thompson JE, Westervelt P, National Comprehensive Cancer Network. Myelodysplastic syndromes. In: J Natl Compr Canc Netw. 9, 13. Ed(s) R Pazdur, LD Wagman, KA Camphausen, WJ Hoskins. CMP Medica: Lawrence, Kansas, USA, 887-903, 1/2011. ISBN: 21233243.
3. Stevenson W, Garcia-Manero G. Myelodysplastic Syndromes. In: Leukemias: Principles and Practice of Therapy, 1. Ed(s) S Faderl, H Kantarjian. Blackwell Publishing Ltd. Oxford, United Kingdom, 99-114, 2011.
4. Faderl SH, Garcia-Manero G, Kantarjian HM. Myelodysplastic syndromes (MDS). In: Management of Hematologic Malignancies. Ed(s) S O'Brien, JM Vose, HM Kantarjian. Cambridge University Press: Cambridge, United Kingdom, 103-115, 2011.
5. Stevenson WS, Bueso-Ramos C, Garcia-Manero G. Myelodysplastic Syndromes: The MD Anderson Cancer Center Approach. In: The MD Anderson Manual of Medical Oncology, 2nd. Ed(s) HM Kantarjian, RA Wolff, CA Koller. McGraw-Hill Companies, Inc. China, 75-95, 2011. ISBN: 978-0-07-170106-8.
6. Fabio Santos, Garcia-Manero, G. Targeted Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndromes. In: Cancer Etiology, Diagnosis and Treatments: Targeted Therapy for Solid Tumors and Hematologic Malignancies. Ed(s) A Quintas-Cardama, DL Gibbons, V Cataldo. Nova Science Publishers, Inc. New York, 75-103, 2011. ISBN: 978-1-61761-854-3.
7. Garcia-Manero G. Therapeutic Modalities. In: The Myelodysplastic Syndromes. Ed(s) J Varkonyi. Springer: London, New York, 219-238, 2011. ISBN: 978-94-007-0439-8.
8. Garcia-Manero G, List A, Kantarjian H, Cortes J. Myelodysplastic syndromes. In: Cancer Management: A Multidisciplinary Approach, 13. Ed(s) R Pazdur, LD Wagman, KA Camphausen, WJ Hoskins. UBM Medica LLC: Norwalk, 887-903, 2010.
9. Atallah E, Garcia-Manero G. Epigenetic Drugs (DNA Demethylating Agents). In: Epigenetics in Biology and Medicine. Ed(s) M Estellar. CRC Press: Boca Raton, FL, 27-48, 2009.
10. Garcia-Manero G, List A, Kantarjian H, Cortes JE. Myelodysplastic Syndromes. In: Cancer Management: A Multidisciplinary Approach, 12. Ed(s) R Pazdur, LD Wagman, KA Camphausen, WJ Hoskins. CMP Healthcare Media LLC: Norwalk, CT, 841-857, 2009. ISBN: 9781891483639.
11. Garcia-Manero G, Issa JP. The role of DNA hypomethylating agents in cancer treatment. In: Progress In Oncology 2004. 6, 131-158, 2004.
12. Garcia-Manero G, Kantarjian H, Schiffer C. Adult acute lymphocytic leukemia. In: Cancer Medicine 6. BC Decker, Inc., 2003.
13. Garcia-Manero G, Talpaz M, Faderl S, Kantarjian H. Chronic myelogenous leukemia. In: Blood: Principles and Practice of Hematology. Lippincott, Williams & Wilkins, 433, 2003.
14. Garcia-Manero G, Kantarjian H. New approaches to the management of patients with the myelodysplastic syndrome. In: The myelodysplastic syndromes. Pathobiology and Clinical Management. Marcel Dekker, 2002.
15. Garcia-Manero G, Martinez J. Principles of hemostasis and thrombosis. In: Management and Prevention and of Thrombosis in Primary Care, 2001.

Letters to the Editor

1. Garcia-Manero G. In reply to 'Improving the prognostic evaluation of patients with lower-risk myelodysplastic syndromes' by Kuendgen et al. Leukemia 23:185, 2009. e-Pub 6/2008. PMID: 18548096.
2. Garcia-Manero G. Chromosomal abnormalities in chronic lymphocytic leukemia. N Engl J Med 344(16):1254, 4/2001. PMID: 11314693.

Grant & Contract Support

Title: MDS Clinical Research Consortium
Funding Source: Aplastic Anemia & MDS International Foundation supported by the Evans Foundation
Role: Co-Chair
Duration: 3/1/2013 - 2/28/2018
 
Title: CA110791: Innate immunity dysregulation in myelodysplastic syndromes
Funding Source: DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role: Co-Investigator
Principal Investigator: Yue Wei
Duration: 9/30/2012 - 9/29/2014
 
Title: Research Training in Academic Medical Oncology
Funding Source: NIH/NCI
Role: Faculty Mentor
Principal Investigator: Waun Ki Hong
Duration: 5/3/2010 - 4/30/2015
 
Title: Analysis of histone code alterations and JMJD3 using CHIP-seq in myelodysplastic syndromes
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 5/1/2010 - 10/31/2013
 
Title: Proteasome/HDAC Inhibition in Leukemia/MDS; Phase 1 Trial and Correlative Studies
Funding Source: NIH/NCI
Role: Principal Investigator-MDACC
Principal Investigator: Steve Grant
Duration: 9/30/2009 - 2/23/2012
 
Title: Developmental Research Project "Histone deacetylase inhibitors in leukemia: understanding the molecular and clinical implications of their use"
Funding Source: NIH/NCI
Role: Project Leader
Principal Investigator: Jean-Pierre Issa
Duration: 9/1/2008 - 8/31/2010
 
Title: Training Program in Biostatistics for Cancer Research
Funding Source: NIH/NCI
Role: Faculty mentor
Principal Investigator: Gary Rosner
Duration: 8/1/2008 - 7/31/2013
 
Title: CTEP study 2005-0031 (Garcia-Manero PI of clinical trial) Phase 1 Studies of Targeted Anti-Cancer Therapies
Funding Source: NIH/NCI
Role: Investigator
Principal Investigator: Razelle Kurzrock
Duration: 4/16/2008 - 1/7/2010
 
Title: Phase I Study of 5-Aza-2’-Deoxycytidine in Acute Lymphocytic Leukemia
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/12/2007 - 8/31/2010
 
Title: Randomized Study of Combined Epigenetic Therapy
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Jean-Pierre Issa
Duration: 9/1/2007 - 7/31/2012
 
Title: Highly Multiplexed Assays on the BioCD for Acute Lymphocytic Leukemia
Funding Source: NIH/NCI
Role: Principal Investigator-MDACC
Principal Investigator: David Nolte
Duration: 9/1/2007 - 8/31/2011
 
Title: Prognostic and Therapeutic Implications of Aberrant DNA Methylation In Acute Lymphocytic Leukemia
Funding Source: Leukemia and Lymphoma Society
Role: Principal Investigator
Duration: 10/1/2006 - 9/30/2009
 
Title: Epigenetic and therapeutic profiling of chronic lymphocytic leukemia
Funding Source: CLL Global Research Foundation
Role: Principal Investigator
Duration: 10/1/2005 - 10/1/2007
 
Title: New Approaches to the Biology and Treatment of MDS
Funding Source: NIH/NCI
Role: Project Leader
Principal Investigator: Hagop M. Kantarjian
Duration: 6/21/2005 - 5/31/2011
 
Title: Cell Cycle Controlling Genes in Adult Acute Lymphoma
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/1/2003 - 8/31/2005
 
Title: Phase I/II study of 5-aza-2'-deoxycytidine and valproic acid in patients with relapsed/refractory leukemias or myelodysplastic syndromes
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/1/2003 - 8/31/2005

Last updated: 5/18/2013